MicroRNA expression profiling in peripheral blood mononuclear cells and serum of type 2 diabetic, pre-diabetic and normo-glycaemic individuals by Dias, Stephanie
  MicroRNA expression profiling in 
peripheral blood mononuclear cells and 
serum of Type 2 diabetic, Pre-diabetic and 
Normo-glycaemic individuals 
by 
Stephanie Dias 
Dissertation presented for the degree of Master of 
Science in Molecular Biology in the  
Faculty of Medicine and Health Sciences at    
Stellenbosch University 
Supervisor: Dr Carmen Pheiffer 
Co-supervisor: Dr Sian Hemmings 
March 2016 
 ii 
 
Declaration 
 
By submitting this thesis/dissertation electronically, I declare that the entirety of the work 
contained therein is my own, original work, that I am the sole author thereof (save to the 
extent explicitly otherwise stated), that reproduction and publication thereof by Stellenbosch 
University will not infringe any third party rights and that I have not previously in its entirety or 
in part submitted it for obtaining any qualification. 
 
March 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2016 University of Stellenbosch 
All rights reserved
Stellenbosch University  https://scholar.sun.ac.za
 iii 
 
Abstract 
 
MicroRNAs (miRNAs) are small non-coding RNAs that play a fundamental role in cellular 
function by regulating messenger RNA gene expression. Alterations in miRNA expression 
are implicated in metabolic dysregulation, with several studies reporting the involvement of 
miRNAs in the pathophysiology of Type 2 diabetes (T2D). Recently, circulating miRNAs 
have attracted considerable interest as biomarkers to identify individuals at risk for T2D, thus 
we hypothesised that circulating miRNA could be used as markers for T2D progression.  The 
aim of this study was to determine whether miRNA expression profiles differ between 
diabetic, pre-diabetic and normo-glycaemic individuals.  
 
Individuals were recruited from local communities and classified as diabetic, pre-diabetic or 
normo-glycaemic according to World Health Organization criteria, whereafter miRNAs were 
extracted from peripheral blood mononuclear cells (PBMCs) and serum of age-, gender-, 
ethnicity- and BMI-matched diabetic (n=4), pre-diabetic (n=4) and normo-glycaemic (n=4) 
individuals. MiRNAs extracted from PBMCs were sequenced using the Illumina HiSeq 2500 
platform, and validated by quantitative real time PCR (qRT-PCR) in PBMCs and serum of 
these individuals. Moreover, bioinformatics was conducted using various target prediction 
programs (TargetScan, DIANA and PITA) and the DAVID functional gene annotation tool to 
assign biological significance to the differentially expressed miRNAs identified by 
sequencing.  
 
Sequencing showed that 267 (pre-diabetics vs. normo-glycaemics), 277 (diabetics vs. 
normo-glycaemics) and 267 (pre-diabetics vs. diabetics) miRNAs were differentially 
expressed between groups. Of these, five differentially expressed miRNAs (miR-27b, miR-
379, miR-21, miR-98 and miR-143) were selected for validation by qRT-PCR in PBMCs. 
Only miR-143 and miR-27b were significantly differentially expressed using qRT-PCR, 
although the results for miR-143 were different compared to the sequencing data. MiR-143 
was upregulated in pre-diabetics compared to normo-glycaemic individuals (1.40-fold, 
p≤0.01), whereas sequencing showed upregulation of miR-143 in diabetics compared to pre-
diabetics (1.75-fold, p≤0.05). The differential expression of miR-27b was consistent between 
qRT-PCR (1.55-fold; p=0.07) and sequencing (1.15-fold; p<0.01), where both methods 
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showed upregulation in pre-diabetics compared to normo-glycaemic individuals. The 
expression of miR-27b was similarly upregulated in serum of pre-diabetics compared to 
normo-glycaemic individuals (2.0-fold; p≤0.05). Furthermore, five novel miRNAs identified by 
sequencing were successfully validated in PBMCs of diabetic, pre-diabetic and normo-
glycaemic individual. 
 
Sequencing and qRT-PCR showed that miR-27b was upregulated in PBMCs and serum of 
pre-diabetics compared to normo-glycaemic individuals. Bioinformatics identified peroxisome 
proliferator-activated receptor gamma (Pparg) as a target for miR-27b. PPARG is an insulin 
sensitizing agent, thus we speculate that increased miR-27b expression in pre-diabetes 
suppresses Pparg, thereby inhibiting insulin signaling and subsequently decreasing glucose 
uptake. The increased insulin and glucose levels observed in the pre-diabetic individuals 
support this idea, although further work is required to confirm this hypothesis. 
 
In conclusion, we showed that miRNA profiles differ during T2D progression, and are able to 
discriminate between diabetic, pre-diabetic and normo-glycaemic individuals. To our 
knowledge, this is the first study to report differential expression of miR-27b during T2D, 
suggesting its potential as a biomarker that could be incorporated into predictive models for 
the identification of high risk individuals. However, miRNA profiling in a larger sample size 
and prospective longitudinal studies are required to assess clinical applicability. 
 
 
 
Words: 500 
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Uitreksel 
 
MikroRNAs (miRNAs ) is klein nie-koderende RNAs wat 'n fundamentele rol in sellulêre 
funksie speel deur regulering van boodskapperRNA geenuitdrukking. Verskeie studies 
ïmpliseer veranderings in miRNA ekspresie met metaboliese disregulering en in die 
patofisiologie van Tipe 2-diabetes (T2D). Onlangs het sirkulerende miRNAs groot 
belangstelling uitgelok as biomerkers om individue te identifiseer wat „n verhoogde risiko vir 
T2D het. Ons hipotese stel dus voor dat sirkulerende miRNA gebruik kan word as merkers 
vir T2D siekteprogressie. Die doel van hierdie studie was om vas te stel of miRNA 
geenuitdrukkings profiele verskil tussen diabete, prediabete en normoglisemiese individue. 
 
Individue wat uit plaaslike gemeenskappe gewerf is, is volgens die Wêreld Gesondheid 
Organisasie riglyne geklassifiseer as diabete, pre diabete of normoglisemiese individue. 
Hierna is miRNAs uit die perifere bloed mononukleêreselle (PBMS) en serum van 
ouderdom, geslag, etniesiteit en liggaamsmassa-indeks vergelykbare diabete (n=4), 
prediabete (n=4) en normoglisemiese individue (n=4), geïsoleer. Die geenvolgordebepaling 
van die geïsoleerde miRNAs is bepaal deur „n Illumina HiSeq 2500 platform, en bevestig 
deur kwantitatiewe “real time PCR” (qRT-PCR). Verder, is bioinformatika uitgevoer met 
behulp van verskeie teikenvoorspellings programme (TargetScan, Diana en PITA) asook 
David se funksionele geenannotasie instrument om biologiese betekenis aan die 
differensieel uitgedrukte miRNAs, te koppel. 
 
Geenvolgordebepaling het getoon dat 267 (prediabete vs. normoglisemies), 277 (diabete vs. 
normoglisemies) and 267 (prediabete vs. diabete) miRNAs differensieel uitgedruk word. 
Hiervan is vyf differensieel uitgedrukte miRNAs (miR-27b, miR-379, miR-21, miR-98 en miR-
143) gekies vir bevestiging deur qRT-PCR in PBMS. MiR-143 en miR-27b differensiasie was 
deur qRT-PCR bevestig, hoewel die qRT-PCR resultate vir miR-143 verskil het met die 
geenvolgordebepaling data. Met qRT-PCR is miR-143 opgereguleer in die prediabete 
teenoor normoglisemiese individue (1,40-voudig, p≤0.01), terwyl met geenvolgordebepaling 
miR-143 in diabete teenoor prediabete (1,75-voudig, p≤0.05) opgereguleer was. Daar was 
ooreenstemming in die differensiële uitdrukking van miR-27b tussen die qRT-PCR (1,55-
voudig; p=0,07) en geenvolgordebepaling (1,15-voudig; p<0,01), waar albei metodes 
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opregulering gewys het in die prediabete teenoor normoglisemiese individue. In die serum 
monsters was die uitdrukking van miR-27b soortgelyk opgereguleer in prediabete (2,0-
voudig; p≤0.05). Verder is vyf unieke miRNAs geïdentifiseer deur geenvolgordebepaling wat 
suksesvol bevestig is in PBMS van diabete en prediabete. 
 
Bioinformatika het Pparg geïdentifiseer as 'n teiken vir miR-27b. PPARG is 'n 
insuliensensiterings agent, dus spekuleer ons dat hoër miR-27b ekspresie, in prediabete 
Pparg onderdruk, wat die insuliensein demp en tot verlaagde glukose opname lei. Die 
verhoogde insulien en glukose vlakke wat in prediabete voorkom ondersteun hierdie idee, 
alhoewel verdere werk nodig is om hierdie hipotese te bevestig. 
 
Ten slotte, het ons getoon dat miRNA profiele tydens die T2D siekteprogressie verskil, en in 
staat is om tussen diabete, prediabete en normoglisemiese individue te diskrimineer. Tot ons 
kennis, dit is die eerste studie wat differensiele uitgedrukking van miR-27b in T2D 
rapporteer, en die potensiële toepassing as 'n nie-indringende biomerker uitwys. Dit kan 
moontlik in voorspellende modelle geïnkorporeer kan word vir die identifisering van hoë 
risiko individue. Maar verdere studies met groter monster getalle en prospektiewe 
longitudinale studies is nodig om die kliniese toepaslikheid te evalueer. 
 
 
Words: 488 
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1. INTRODUCTION 
1.1 The global burden of Diabetes mellitus 
Diabetes mellitus (DM) is characterized by persistent hyperglycaemia (fasting blood glucose 
≥7.0 mmol/L), caused by defects in insulin secretion by pancreatic beta (β)-cells  and/or 
insulin action in peripheral tissue such as, skeletal muscle, liver and adipocytes (Fernandez-
Valverde et al., 2011; Tripathy and Chavez, 2010). According to the International Diabetes 
Federation (IDF), approximately 382 million people worldwide had diabetes in 2013 and this 
number is expected to increase to more than 592 million people by 2035 (Fig.1.1) (IDF, 
2013). The prevalence of DM in the African region is projected to increase from 19.8 million 
cases in 2013 to 41.5 million cases in 2035, representing an approximately 109% increase in 
people afflicted with the disease (Fig.1.1). Conservative estimates indicate that South Africa 
currently has the fifth highest prevalence (9.3%) of DM in Africa (IDF, 2013), which vary 
between ethnic groups and regions (Erasmus et al., 2012). In 2005, the South African 
Medical Research Council conducted a study on chronic diseases of lifestyle in South Africa 
between 1995 and 2005. This study revealed that the highest prevalence of DM was among 
the Indian community at 8.5% and 11.5%, followed by the mixed ancestry community with a 
prevalence of 3.1% and 5.8% for men and women, respectively (Goedecke et al., 2005). The 
lowest prevalence of DM was observed among males and females in the Northwest province 
of South Africa at 0.9% and 1.1%, respectively (Goedecke et al., 2005). However, recent 
studies have shown an increase in the prevalence of T2D in the mixed ancestry community 
in the Western Cape of South Africa (Erasmus et al., 2012). 
 
The major types of DM include Type 1 DM (T1D), Type 2 DM (T2D), Gestational DM and 
Maturity onset diabetes of young (MODY) (American Diabetes Association 2014). Type 2 
diabetes (T2D), also called non-insulin dependent diabetes (NIDDM) or adult-onset diabetes, 
is the most common form of diabetes accounting for approximately 90% of all cases 
worldwide, while T1D, gestational DM and MODY make up the remaining 10% (ADA, 2014; 
Butt and Swaminathan, 2015). Type 1 diabetes mellitus is referred to as insulin-dependent 
diabetes mellitus (IDDM), and occurs due to the inability of the pancreas to secrete insulin 
due to β-cell destruction, thus, requires insulin to maintain normo-glycaemia. Gestational DM 
is defined as glucose intolerance first diagnosed during pregnancy, and it is estimated that 
approximately 5-10% of all pregnancies are complicated by hyperglycaemia (Gunderson et 
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al., 2014).  Most cases of GDM resolve after delivery, however, these women have a greater 
than 70% lifetime risk of developing T2D (Ratner, 2007). Maturity onset diabetes of the 
young (MODY) occurs due to an autosomal dominant genetic mutation, and is characterized 
by impaired insulin secretion, with little or no defects in insulin action (Shields et al., 2010). 
Figure 1.1 The global prevalence of diabetes in 2013 and the predicted global prevalence in 2035 
(Adapted from: IDF, 2013). 
 
1.2 Aetiology of Type 2 diabetes 
Type 2 diabetes is a complex, multifactorial disease involving the interplay of many risk 
factors. These include, amongst others, genetics, lifestyle, nutrition and lack of physical 
activity (Fig. 1.2) (Hu, 2011; Wild et al., 2004; Zimmet et al., 2014).   
 
Over 70 susceptibility loci have been identified for T2D (Sun et al., 2014b), however, these 
account for only approximately 5-10% of all cases, suggesting that the increasing prevalence 
of T2D is not driven by genetic factors (McCarthy and Menzel, 2001). Indeed, several lines 
of evidence have suggested that an unhealthy diet, high in fats and sugars, together with a 
sedentary lifestyle are the main contributors of the current T2D pandemic (Wing et al., 2001). 
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Reports that the increased rates of T2D in developing countries, are due to, amongst others, 
increased prosperity, urbanization and a shift towards a “westernized lifestyle” (Ostbye et al., 
1989), confirm the importance of diet and physical activity in the development of T2D. The 
“westernized lifestyle” is characterized by high caloric intake (Hu, 2011; Popkin, 1999; 
Popkin and Gordon-Larsen, 2004) that is associated with highly processed and refined 
foods, which contain high levels of salt, sugars and fats (Odermatt, 2011), a sedentary 
lifestyle (Popkin, 1999), smoking, and alcohol consumption, (Hu, 2011), among others.  
 
 
 
 
.  
 
 
 
 
   
Figure 1.2 Interaction between genetic and environmental factors that contribute to the development of 
T2D. 
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1.3 Major metabolic mechanisms that characterize 
Type 2 diabetes 
As discussed previously T2D is a complex disease underpinned by a number of biological 
mechanisms. These mechanisms primarily include impaired insulin action, β-cell 
dysfunction, increased endogenous glucose output and obesity. These will be discussed 
below.  
1.3.1 Insulin resistance 
1.3.1.1 Insulin action  
Insulin, a peptide hormone secreted by β-cells in the pancreas, is secreted in response to 
elevated blood glucose levels (Kahn, 1998). The effect of insulin on glucose metabolism 
varies in different tissue types. Insulin regulates the metabolism of carbohydrates and fats by 
promoting the absorption of glucose from the blood in skeletal muscle, and promoting fat 
storage in adipose tissue (Saltiel and Kahn, 2001). Insulin also inhibits hepatic glucose 
production by inhibiting gluconeogenesis (glucose production) (Claus and Pilkis, 1976) and 
glycogenolysis (glycogen breakdown) (Marks and Botelho, 1986). 
1.3.1.2 Insulin signaling  
Insulin is the primary mediator of glucose homeostasis (Leahy, 2005). During conditions of 
hyperglycaemia, β-cells in the pancreas increase their secretion of insulin to stimulate 
glucose uptake in insulin-responsive tissues such as the skeletal muscle so as to restore 
normo-glycaemia (Araujo et al., 2013). Insulin initiates its biological action by binding to the 
tyrosine kinase insulin receptor located in the plasma membrane of insulin-responsive 
tissues. Phosphorylation of the insulin receptor results in the activation of a number of 
signaling cascades that regulates several biological processes including glucose uptake 
(Fig. 1.3). Activation of the insulin signaling cascade leads to the translocation of glucose 
transporter type 4 (GLUT4) to the cell membrane and the uptake of glucose from the 
circulation (Frosig et al. 2007). Skeletal muscle is considered the predominant site for 
insulin-mediated glucose disposal, and accounts for approximately 80% of peripheral 
glucose uptake in the postprandial state (Defronzo et al., 1981; Defronzo and Tripathy, 
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2009). Dysregulation of any intracellular protein (protein kinase C (PKC), insulin receptor 
substrate 1/2 (IRS1/2) or phosphatidylinositol 3-kinase/serine-threonine protein kinase-1 
(PI3K/AKT-1)) involved in the insulin signaling cascade leads to the development of insulin 
resistance (IR) (Kahn, 1998). The nature and extent of cellular IR depends on the tissue 
type, and vary according to the metabolic action of insulin within the tissue (Poornima et al., 
2006). 
 
 
 
 
Figure 1.3 Insulin signaling cascades (Adapted from: Li and Zhang, 2007).  
1.3.1.3 Insulin resistance and fatty acids 
Fundamental in the progression of T2D, are the deleterious effects of increased lipid 
accumulation and adipocyte hypertrophy and hyperplasia, which leads to the dysregulation 
of adipocyte control mechanisms and the recruitment of macrophages into adipose tissue, 
inflammation and the release of several factors that further exacerbate the IR state 
(Greenberg and Obin, 2006).  
Key: protein tyrosine phosphatase-1B (PTP-1B), growth factor receptor bound protein 2 (Grb2), 
SHC-transforming protein (SHC), protein subfamily SOS/Ras, mitogen-activating protein kinase 
(MAPK/MEK), cbl-associated protein complex (cbl/CAP), insulin receptor substrate 1/2/3/4, 
phosphatidylinositol 3-kinase/serine-threonine protein kinase-1 (PI3K/Akt), PI3k- dependent 
serine/threonine kinase (PDK), atypical protein kinase C (aPKC), glycogen synthase kinase 3 
(GSK3),  (AKT), preproinsulin (PPI), p70 ribosomal subunit S6 kinase (p70S6k), glucose-6-
phosphate (G-6-P), glucose transporter 4 (GLUT4). 
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Several studies have suggested that increased levels of non-esterified fatty acids (NEFA) 
during disease progression alter insulin signaling pathways through different mechanisms 
(Poornima et al., 2006). For example, Shulman et al. (2000) suggests that elevated levels of 
fatty acids inhibit the insulin signaling pathway, by activating PKC; an important intracellular 
insulin signaling protein (Shulman et al., 2000). Activation of PKC leads to serine/threonine 
phosphorylation on the IRS-1/2, failure to activate PI3K, and decreased translocation of 
GLUT4 to the cell membrane, and subsequently decreased glucose uptake into the cell 
(Dresner et al. 1999; Shulman, 2000). Others have also reported that fatty acids can inhibit 
insulin signaling through PKC-independent pathways, where fatty acids induce IR in cells by 
attenuating insulin receptor gene expression (Bhattacharya et al., 2007; Dey et al., 2005). 
These examples confirm that NEFAs play a significant role in altering cellular insulin 
signaling pathways, thereby contributing to IR. 
 
Furthermore, studies have suggested that elevated levels of glucose and fatty acids may 
impair β-cell function, and at a later stage, affect β-cell survival (Morgan, 2009; Purrello and 
Rabuazzo, 2000). It is generally agreed that both IR and β-cell dysfunction play important 
roles in the pathogenesis of T2D, although there is uncertainty about the relative contribution 
of these factors (Scheen, 2003; Kahn, 2003). 
1.3.2 Beta-cell dysfunction 
The primary function of β-cells is to synthesize and release insulin in response to increased 
blood glucose concentrations, thus restoring homeostasis. The process of insulin secretion 
is disrupted in dysfunctional β-cells as a result of irreversible damage to cellular components 
of insulin production over time (Stumvoll et al., 2005). Several mechanisms including 
glucotoxicity, lipotoxicity, and amyloid formation have been proposed as a direct link to β-cell 
dysfunction (Biden et al., 2014; Maedler, 2008; Stumvoll et al., 2005). The glucotoxic 
condition (chronic hyperglycaemia exposure) is characterized by decreased insulin gene 
transcription, due to hyperglycaemia-induced loss of critical proteins that activate the insulin 
promoter (Kaiser et al., 2003). The effect of hyperglycaemia on β-cells is often followed by a 
reduction in β-cell mass, as a result of β-cell apoptosis, without a compensatory increase in 
proliferation or neogenesis (cell renewal) (Bonner-Weir and O'Brien, 2008; Meier and 
Bonadonna, 2013).  
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The detrimental effects of excess glucose converge with the adverse consequences of 
lipotoxicity, both of which cause increased β-cell apoptosis. Lipotoxic conditions are induced 
in β-cells during chronic exposure to elevated levels of NEFAs, which is a characteristic of 
obesity and T2D (Kahn et al., 2014). Chronically elevated NEFAs and the accumulation of 
long-chain acyl coenzyme A inhibit insulin secretion, as a result of pre-existing 
hyperglycaemia and glucose-induced fatty acid oxidation (Robertson et al., 2003; Stumvoll et 
al., 2005). In addition, elevated glucose concentrations increase the levels of reactive 
oxygen species, thereby inducing oxidative stress in β-cells over time. Pancreatic β-cells are 
particularly sensitive to oxidative stress due to their low intrinsic antioxidant capacity, thus 
oxidative stress may further exacerbate the impairment of β-cells during the development of 
T2D (Drews et al., 2010).  
1.3.3 Obesity 
Obesity is currently a major health concern, affecting more than 475 million adults and 200 
million school-aged children globally (World Obesity, 2012). The increasing prevalence of 
T2D is concurrent with the rising rates of obesity, and appears to reflect common 
environmental and genetic factors that underlie both conditions (Feero et al., 2010; Hu, 
2011). Indeed, overweight and obesity is widely considered to be the major driver of T2D, 
and studies have reported that 90% of adults with T2D are overweight or obese (Whitmore, 
2010). These conditions are characterized by the excessive accumulation of body fat due to 
an imbalance between energy intake and expenditure, i.e. increased consumption of high 
fat, nutrient poor foods and decreased physical activity (Misra et al., 2009). The body mass 
index (BMI), is a tool used to calculate overweight and obesity, and individuals with a BMI of 
≥25 kg/m2 or ≥30 kg/m2 is defined as overweight or obese, respectively (Puoane et al., 
2002). Obesity is often associated with hypertension, low serum high-density-lipoprotein 
(HDL) cholesterol concentrations, and high serum low-density-lipoprotein (LDL) cholesterol, 
triglyceride and non-HDL cholesterol concentrations (Han et al., 1998; Mooradian, 2009; 
Pradhan et al., 2001). Together these factors are referred to as the metabolic syndrome, a 
risk factor for a number of chronic diseases, including T2D, and present major future 
challenges in reducing T2D mortality.   
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1.4 Progression of Type 2 diabetes 
Type 2 diabetes is a chronic disease that progresses and worsens over time (Fig. 1.4). The 
disease is usually diagnosed during the later stages of disease progression, when insulin 
sensitivity and β-cell function is already significantly impaired. Together, the effects of 
increased IR and impaired β-cell function exacerbate hyperglycaemia, ultimately resulting in 
insulin deficiency and excess glucagon production (Fanelli et al., 2006). Chronic 
hyperglycaemia leads to many long-term complications in the nerves, heart, kidney, eyes 
and blood vessels that cause irreversible tissue damage. Individuals with pre-diabetes, 
defined as having higher glucose levels than normal, but not high enough to be considered 
as T2D are also at risk of these micro- (nephropathy, neuropathy and retinopathy) and 
macro-vascular (coronary artery disease, stroke and peripheral arterial disease) 
complications (Fowler, 2008; Vinik and Flemmer, 2002). The risk of diabetic retinopathy and 
nephropathy, caused by progressive damage to the retina and kidney failure, respectively, is 
related to the severity of hyperglycaemia and the presence of hypertension in the pre-
diabetic stage (Fowler, 2008). The risk for diabetic neuropathy is increased, depending on 
both the magnitude and duration of hyperglycaemia exposure, before the development of 
T2D. This is indicated by the presence of symptoms and/or signs of peripheral nerve 
dysfunction (Fowler, 2008). The central pathological mechanism in macrovascular disease is 
the process of atherosclerosis, which leads to the hardening and narrowing of arterial walls 
throughout the body. Atherosclerosis is thought to result from chronic inflammation and 
injury to the arterial wall, which leads to increased risk of developing cardiovascular disease 
(CVD) (Boyle, 2007). Conservative estimates indicate that more than 70% of patients with 
T2D die of cardiovascular causes (Laakso, 2010). 
 
Taken together, these studies emphasize the need to detect T2D early, or to identify high 
risk individuals in the early stages, thereby, preventing or delaying T2D disease progression, 
and ultimately reducing mortality and morbidity worldwide. A number of studies have already 
reported that the benefits of the early detection and treatment of T2D can improve 
prognosis/management, and reduce T2D-related complication (Callejas et al., 2013; 
Shamoon et al., 1993; Tuomilehto et al., 2001).  
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Figure 1.4 Type 2 diabetes disease progression (Adapted from: AACE diabetes resource centre, 
2013). 
 
1.5 Diagnosis of Type 2 diabetes 
Diabetes is diagnosed according to the American Diabetes Association (ADA) or WHO 
criteria, by a fasting plasma glucose (FPG) concentration > 7.0 mmol/L, or a two-hour 
plasma glucose concentration during an oral glucose tolerance (OGTT) of > 11.0 mmol/L 
(Table 1.1). The FPG test measures glucose levels after fasting overnight for at least 8 hrs, 
while the OGTT test measures glucose tolerance after ingesting 75 g of glucose diluted in 
water. Glycated haemoglobin A1c (HbA1c) refers to the binding of glucose to haemoglobin, 
and due to the life-span of haemoglobin, reflects average glucose control over a three month 
period. The ADA has recently recommended that HbA1c > 6.5% can be used to diagnose 
diabetes (ADA, 2014).  
 
Glucose measuring devices such as a glucometer (finger prick) may be used as a quick 
indicator of high blood glucose concentrations, but are not considered accurate enough for 
diagnosis. Additionally, a random plasma glucose concentration (RPG) > 11.1 mmol/L may 
be used to indicate possible T2D, although a confirmatory test is required (ADA, 2014).  
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Currently, the FPG and OGTT are the preferred tests for diagnosing diabetes. However, 
OGTT has been regarded as clinically impractical due to the 2 hour waiting period, and has 
led to the FPG being the most common test used to diagnose T2D globally. Literature 
suggests that more than one test should be used to accurately diagnose diabetes or 
hyperglycaemia (Barr et al., 2002; Wang et al., 2002), however, criteria for diagnosing T2D 
varies greatly throughout the world. 
 
The various criteria and cut-off values used for the diagnosis of diabetes include FPG, 
HbA1c and OGTT, as presented in Table 1.1 (Malkani and DeSilva, 2012). The same tests 
are used for both screening and diagnosis, and are based on the 2015 ADA guidelines and 
the 2006 WHO addendum report (ADA, 2015; WHO, 2006). A number of European 
countries, as well as South Africa (Amod et al., 2012) prefer to use the WHO diagnostic 
criteria, while others in America prefer to use the ADA diagnostic criteria (ADA, 2015; 
Deckers et al., 2006).  
 
Table 1.1 The current ADA and WHO diabetes diagnostic criteria (ADA, 2015; WHO, 2006). 
 WHO criteria ADA criteria 
FPG                                        Normal: 
IFG: 
Diabetic: 
< 6.1 mmol/L 
6.1-6.9 mmol/L 
≥ 7.0 mmol/L 
< 5.6 mmol/L 
5.6-6.9 mmol/L 
≥ 7.0 mmol/L 
OGTT (2hr plasma)               Normal: 
IGT:  
Diabetic: 
< 7.8 mmol/L 
7.8-11.0 mmol/L 
≥ 11.1 mmol/L 
< 7.8 mmol/L 
7.8-11.0 mmol/L 
≥ 11.1 mmol/L  
HbA1C                                   Normal: 
Pre-diabetes: 
Diabetes: 
Not specified 
Not specified 
≥ 6.5% 
< 5.7% 
5.7-6.4% 
≥ 6.5% 
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 1 INTRODUCTION 
 
11 
 
1.5.1 Pre-diabetes 
Pre-diabetes is widely considered to be an intermediate state of hyperglycaemia (Beagley et 
al., 2014), and is often refered to as a state of impaired fasting glucose (IFG) or impaired 
glucose tolerance (IGT). Although controversy exists regarding the diagnostic criteria for pre-
diabetes, many studies have reported that it is a very high predictor for the development of 
overt diabetes and related complications (WHO, 2006; Forouhi et al., 2006). It is estimated 
that approximately 5%-10% of all pre-diabetes cases convert to T2D yearly. The WHO 
classifies IFG and IGT at 6.1-6.9 mmol/L (FPG) and 7.8-11.0 mmol/L (OGTT) cut-off values, 
respectively (WHO, 2006), while the ADA uses the same cut-off for IGT, but has a lower 
threshold for IFG (5.6-6.9 mmol/L) (ADA, 2015). Their rationale is based on data which 
showed that individuals with FPG concentrations between 5.6 mmol/L and 6.05 mmol/L were 
at increased risk of developing T2D and CVD, which would not be identified if a FPG cut-off 
threshold of 6.1-6.9 mmol/L was used (Gabir et al., 2000; Shyong Tai et al., 2004). However, 
Ferouhi et al. 2006 showed that the lowered threshold values (5.6-6.9 mmol/L) improved the 
sensitivity of IFG as a predictor of diabetes, but at the cost of specificity, thus 
misrepresenting the amount of individuals at risk of developing diabetes (Forouhi et al., 
2006; Sacks et al. 2011). Furthermore, the ADA has an additional HbA1c test at a cut-off 
value of 5.7-6.4% for detecting pre-diabetes, which is not defined in WHO (ADA, 2015). 
1.6 Limitations and shortfalls of current diagnostic 
tests 
In certain cases, the glycaemic status of patients may vary when different tests are used. 
Such variability may arise due to changes that occur over time, measurement variability, or 
because FPG, OGTT and HbA1c measure different physiological processes during the 
pathogenesis of T2D (Selvin et al., 2007). In addition to these factors, evidence suggests 
that several technical challenges are associated with each individual diagnostic test, and 
could impede the diagnosis of T2D. Furthermore, current available diagnostic tests by FPG, 
HbA1c and OGTT are limited with regards to predicting diabetes; as it does not allow the 
identification of individuals who are susceptible to develop diabetes when glucose levels are 
still considered normal, thus increasing the risk of developing several health complications. 
However, in the absence of a more specific biological marker to define diabetes, plasma 
glucose estimation remains the basis of diagnostic criteria (Molleutze, 2006). 
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1.6.1 Oral glucose tolerance test and fasting plasma 
glucose test 
The OGTT is currently the gold standard for the diagnosis of T2D due to its superiority in 
diagnosing diabetes in the clinical setting compared to the FPG test (Salmasi and Dancy, 
2005). However, the OGTT requires very stringent conditions, such as overnight fasting, 
multiple blood sampling, consumption of 75 grams (g) of glucose diluted in water, and 
preventing the subject from movement for the duration of the test (Appajigol et al., 2011). 
These conditions influence the test results, often making the test impractical. Moreover, the 
OGTT has greater inter-individual variability compared to the FPG test and HbA1c, and it is 
recommended that the test be confirmed by repeat testing on a different day (Selvin et al., 
2007; Waugh et al., 2007). Therefore, due to these limitations, the ADA recommended FPG 
as the preferred glucose-based diagnostic test (International Expert Committee, 1997). 
However, FPG lacks sensitivity and results in lower disease prevalence compared to OGTT, 
and moreover, cannot identify subjects with IGT (Waugh et al., 2007). A study investigating 
glycaemia in a black South African population illustrated that the prevalence of T2D would 
be lower if FPG was solely used for diagnosis compared to using both FPG and OGTT 
(Motala et al., 2008). This illustrates the different underlying pathophysiologies of T2D, and 
suggests that more specific tests are required to accurately diagnose diabetes.  
1.6.2 Glycated haemoglobin A1c 
The use of HbA1c has a number of advantages compared to glucose measurements by 
FPG and OGTT. These advantages include no fasting, less variability, greater pre-analytical 
stability, and a greater index for overall glycaemic control. However, there are a number of 
factors that could lead to the misinterpretation of HbA1c diagnostic measurements. These 
factors include altered red blood cells in patients with haemoglobinopathies, and variations 
due to iron deficiency, aging, ethnicity and antiretroviral drugs (Church and Simmons, 2014; 
International Expert Committee, 2009; Kilpatrick and Winocour, 2010; Kirkman and Kendall, 
2011; Saudek et al., 2008; Topic, 2014). These factors hamper the use of HbA1c, especially 
in countries where the prevalence of these disorders are high. For example, South Africa is a 
multi-ethnic country that currently has the highest prevalence of Human Immunodeficiency 
Virus Infection/Acquired Immune Deficiency Syndrome (HIV/AIDS) globally, therefore 
decreasing the predictive value of HbA1c (HIV and AIDS in South Africa, 2014). Indeed, a 
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recent analysis has precluded its use for diagnosing diabetes in a South African setting 
(George, 2011). The limitations of the current diagnostic tests underscore the need to 
identify new methods to diagnose T2D more accurately. 
1.7  Biomarkers 
Biomarkers are indicators of normal biological processes that can be used as indicators of a 
particular disease state or other biological states of organisms. They are clinically useful 
because they can potentially predict or diagnose disease, give insight into the 
pathophysiology of disease, and can be used to monitor or predict clinical outcome (Sahu et 
al., 2011). Although the term „biomarker‟ is fairly new, it has been used for many years in 
clinical diagnosis and research. Examples of a few well-known biomarkers include pulse and 
blood pressure (hypertension), cholesterol (coronary and vascular disease), C-reactive 
proteins (inflammation), and  HbA1c, FPG, RPG and OGTT (diabetes) (Kumar and Khanna, 
2011; Sahu et al., 2011). However, biomarkers need to fulfil several criteria to be clinically 
useful. Among others, these include: 
 Tissue or pathology specificity, 
 Easily accessible through minimally invasive methods to collect biofluids, 
 Sensitivity to relevant changes in the disease, 
 Early detection of disease before clinical symptoms appear, 
 A long half-life within the sample,  
 Optimal speed, accuracy and ease of analysis, 
 Cost effective and reproducible, and 
 The ability to differentiate between pathologies (Etheridge et al., 2011; Sahu et al., 
2011) 
Effective biomarkers are ones that are able to monitor and accurately identify individuals at 
the subclinical stage and enable preventative measures before the disease develops (Lyons 
and Basu, 2012). 
1.7.1 Recent advances in biomarker discovery 
A number of genomic, transcriptomic, proteomic, and metabolic markers currently exist, and 
have been correlated with T2D disease progression (Bain et al., 2009; Galazis et al., 2013; 
McKillop and Flatt, 2011). However, these biomarkers often lack sensitivity and/or specificity 
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and are associated with the irreversible stages of T2D (Galazis et al., 2013). Identification of 
novel biomarkers that fulfill some of the criteria listed in section 1.7 would be of great clinical 
value and would have the potential to facilitate intervention strategies that can be tailored to 
the characteristics of an individual to prevent or modify disease progression (Lyons and 
Basu, 2012). Recent advancements in the field of molecular biology have led to the 
development of molecular biomarkers that are easily measured in biological samples such 
as plasma, serum, and whole blood (Chen et al., 2008; Holland et al., 2003). 
1.8 Epigenetics 
Epigenetics is defined as the heritable changes in gene expression or phenotype that occurs 
without changes in the underlying DNA sequence (Christensen and Marsit, 2011). Recent 
findings suggest that epigenetics underpins the crucial link between environmental factors 
and genetic predisposition in the pathogenesis of T2D. Environmental exposures such as 
nutrition, toxins, age, physical inactivity, etc. modify the epigenome, causing epigenetic 
dysregulation; a key mechanism underlying the development of metabolic diseases 
(Hamilton, 2011). Recently, epigenetic mechanisms have attracted considerable interest as 
potential biomarkers which would identify T2D. Moreover, due to their reversible nature, 
epigenetic changes may provide a window of opportunity for intervention strategies to 
prevent or delay the progression to T2D (Reddy et al., 2013). 
 
These epigenetic mechanisms include DNA methylation, loss of genomic imprinting, 
chromatin remodeling and non-coding RNA (Gibney and Nolan, 2010; Hirst and Marra, 
2009). Non-coding RNAs include long non-coding and short-non-coding RNAs such as 
microRNAs that are able to positively and negatively regulate gene expression in a signaling 
cascade (Stefani and Slack, 2008; Wahlestedt, 2013).  
1.9 MicroRNAs 
MicroRNAs (miRNAs) are a class of small, highly conserved non-coding RNA molecules that 
have recently attracted considerable interest as epigenetic modulators of gene expression in 
a wide range of diseases, including T2D (Kong et al., 2011; Olson, 2014; Schwarzenbach et 
al., 2014). MiRNAs are single-stranded RNA species approximately 22 nucleotides (nt) in 
length, that are able to regulate gene expression by inducing repression of target messenger 
RNA (mRNA) through translational inhibition or initiating mRNA degradation (Brennecke et 
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al., 2005). Since their discovery in C. elegans in 1993 (Lee et al., 1993), over 1000 miRNAs 
have been identified in humans, where they regulate a large proportion of genes in the 
human genome (Ardekani and Naeini, 2010). MiRNAs play a critical role in gene regulation 
and have been shown to be involved in highly regulated processes including differentiation, 
apoptosis, proliferation and metabolic processes (Du and Zamore, 2005). Furthermore, 
miRNAs have been extensively studied to understand the regulatory mechanisms involved in 
the pathogenesis of diseases, such as neurological disorders, CVD, obesity and T2D 
(Creemers et al., 2012; Guay et al., 2011; Kong et al., 2011; Zampetaki et al., 2010; 
Zampetaki et al., 2012; Hamilton, 2011; Pinney and Simmons, 2010). These miRNA 
regulatory mechanisms may offer new opportunities for the early detection of T2D and 
associated disorders, which can be used in clinical diagnostics to identify points between 
exposure and disease. 
1.9.1 MicroRNA nomenclature  
For ease of understanding and identification of experimentally confirmed miRNAs, a 
nomenclature system has been adopted. Briefly, the numbering of newly identified miRNAs 
is sequential, and is attached to the prefix „mir‟ followed by a dash (-). The uncapitalized „mir‟ 
refers to the pre-miRNA and the capitalized „miR‟ refers to the mature form. MiRNAs are 
named using the prefix „miR‟, followed by the unique identifying number prescribed to each 
miRNA in the numerical order of discovery (for eg. miR-1, miR-2, miR-3 etc.) (Wright and 
Bruford, 2011). When two mature miRNAs originate from either the 3‟ or 5‟ arm of the same 
pri-miRNA, they are denoted with either a „-3p‟ or „-5p‟ suffix, respectively, at the end of each 
miRNA (for eg. miR-1-3p or miR-1-5p) (Issler and Chen, 2015). However, when the mature 
miRNA found from one arm is more abundant than that from the other, an asterisk (*) 
following the miRNA name is denoted for the miRNA with the lowest concentration (Bartel, 
2004). For example, miR-1 and miR-1* share a pri-miRNA hairpin, but higher concentrations 
of miR-1 is found in the cell.  
 
MiRNAs with nearly identical mature sequences are annotated with lower case letter to show 
their similar structure (for example, miR-1a and miR-1b). Distinct precursor sequences and 
genomic loci from different regions of the genome that express identical mature sequences, 
are distinguished with an additional number (for example, miR1a-1 and miR-1a-2) (Issler and 
Chen, 2015). MiRNAs are also annotated according to the species they are observed in, and 
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are designated with a three-letter prefix. For example, has-miR-1-3p is observed in Homo 
sapiens (human), while mmu-miR-1-3p is observed in Mus musculus (mouse) (Ambros et 
al., 2003). 
1.9.2  MicroRNA biogenesis and mechanism of action 
The biogenesis of miRNAs begins in the nucleus of the cell, where several primary miRNA 
sequences (pri-miRNAs) are transcribed by either RNA polymerase II or RNA polymerase III 
depending on promoter and terminator sequences (Cai et al., 2004), and then capped, 
spliced and polyadenelated. Thereafter, pri-miRNAs are processed by microprocessor 
complex Drosha (a nuclear RNase III enzyme) and DGCR8 (encoded in humans by 
DiGeorge critical region 8) into precursor miRNAs (pre-miRNAs) of ~60-70 nt long stem-loop 
structures (Lee et al., 1993; Muhonen and Holthofer, 2009). These pre-miRNAs are then 
exported from the nucleus to the cytoplasm by Exportin-5 (xpo5) and RanGTP complex. In 
the cytoplasm, pre-miRNAs are further processed and cleaved into ~22 nt long mature 
miRNA duplexes by Dicer, a cytoplasmic RNase III enzyme and its interacting partner, a 
transactivation-responsive RNA binding protein (TRBP or TARBP2) (Liu et al., 2008; Pandey 
et al., 2009). Having lower thermodynamic stability, the 5‟ end of the miRNA duplex is 
selected by the miRNA-induced silencing complex (miRISC), and is subsequently bound to 
the Argonaute protein, which forms part of the risk effector complex. The bound mature 
miRNA guides the miRISC to the 3‟ untranslated region (UTR) binding site of the target 
mRNA, where they are able to downregulate gene expression (Richard et al., 2005). This 
may be achieved by two posttranscriptional mechanisms, namely, mRNA 
cleavage/degradation or translational repression (Kumar and Khanna, 2011) (Fig.1.5). 
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Figure 1.5 Schematic diagram representing the biogenesis of miRNA and its mechanism of action. 
Primary miRNA transcripts (pri-miRNA) transcribed by RNA Polymerase (pol II or III) and processed 
by microprocessor (Drosha and DGCR8), are exported as pre-miRNAs into the cytoplasm by 
Exportin-5 and RanGTP. Dicer and its interacting binding protein TRBP process pre-miRNAs into 
short miRNA duplexes. The 5‟ mature miRNA strand binds to the RNA-induced silencing complex 
(miRISC)-associated argonaut protein (Ago2), and induces silencing of their mRNA target sequences. 
 
The basic difference between mRNA cleavage and translational repression is governed by 
the levels of complementarity between miRNAs and their target mRNA transcripts (Bartel, 
2004). In plants and in a small class of eukaryotes, miRNAs bind to a single, generally 
perfect or near perfect complimentary site in either the coding or 3‟ UTR of the target mRNA, 
which results in  target cleavage and degradation (Ghosh, 2011). In contrast, in most 
investigated animals (mammals), miRNAs bind to multiple, imperfect complementary sites in 
the 3‟ UTR target region, and directs the inhibition of protein accumulation through 
translational repression (Pillai et al., 2007). The complementarity is usually restricted to the 
5‟ end of the mature miRNA, at position 2 to 8, known as the miRNA „seed region‟, a 
sequence that occurs when the nucleotide adenine (A) pairs with uracil (U) and guanidine 
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(G) pairs with cytosine (C) (Xu et al., 2014) (Fig.1.6). However, when the nucleotide 
represents a G or a U, the pairing may be less specific, where two bases can be 
interchangeably recognised by the mRNA, more commonly known as wobble paring 
(Peterson et al., 2014). A perfect seed match between the miRNA and mRNA target has no 
gaps in the alignment, and is regarded to be the most important feature for miRNA target 
recognition in mammals (Lewis et al., 2003). Moreover, a number of miRNA target predicting 
analyses showed that the miRNA target sequence is highly conserved across species, and 
requires a number of base matches flanking the seed sequence to direct the specificity of 
miRNA:mRNA interactions (Lewis et al., 2005; Peterson et al., 2014). Although 
understanding of miRNA function is limited, enough evidence exists to illustrate that a given 
miRNA is able to regulate multiple mRNA targets in a signaling cascade (Friedman et al., 
2009; Lewis et al., 2005), and is therefore involved in controlling many biological processes 
to maintain metabolic homeostasis (Felekkis et al., 2010).  
 
 
 
 
 
Figure 1.6 Schematic overview of the miRNA:mRNA target interaction. Watson-crick base pairing of 
the miRNA seed sequence and the mRNA target sequence is shown in red, and an example of a G-U 
wobble in the seed sequence is shown in green. Flank refers to the 5‟ or 3‟ mRNA sequence 
corresponding to the region on either side of the seed sequence (Adapted from: Peterson et al., 
2014). 
1.9.3 The role of microRNAs in Type 2 diabetes 
The majority of miRNAs is tissue and cell type specific, and plays a critical role in gene 
regulation, while others may be expressed ubiquitously depending on their function (Lagos-
Quintana et al., 2002; Lim et al., 1999; Mao et al., 2013). Recently, scientists have shown 
that miRNA expression is regulated by environmental factors, which contribute to the 
aberrant gene expression patterns seen in metabolic disorders (Rottiers and Näär, 2012). 
The dysfunction of miRNA regulation disrupts normal cellular activity which may lead to the 
development of various diseases, such as cancers, lymphomas, CVD complications, T2D 
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and neurological disorders such as Parkinson‟s and Alzheimer‟s disease (Cheng and Zhang, 
2010; Cuk et al., 2013; Maes et al., 2009). Recently, there has been considerable interest in 
understanding the RNA regulatory phenomena and how miRNAs function in the 
development of T2D (Guay et al., 2011).  
 
In the context of T2D, miRNAs are widely expressed in blood, pancreas, liver, skeletal 
muscle and adipose tissue, and are able to regulate the expression of multiple genes 
(Rottiers and Näär, 2012). Together, these miRNAs regulate insulin sensitivity mainly by 
targeting insulin receptors and the components of insulin/protein kinase B (PKB) signaling 
pathways or GLUT4- mediated glucose uptake and metabolism (Tang et al., 2008). Global 
miRNA profiling has provided valuable information that couples miRNA expression changes 
occurring in pancreatic β-cells and insulin target tissues, with the changes that occur in 
glucose levels during the pathogenesis of T2D (Guay et al., 2011). For example, Herrara et 
al., (2010) measured the expression of several miRNAs in the liver, skeletal muscle and 
adipose tissue in spontaneously diabetic (Goto-Kakizaki) and normo-glycaemic (Brown-
Norway) inbred rats, and found that expression of several miRNAs correlated with the 
glycaemic status of the rats. Each miRNA showed a significant tissue-specific expression 
pattern that varied between the different strains of rats, and between normal and diabetic 
within each strain (Herrera et al., 2010; Herrera et al., 2009). Moreover, prolonged in vitro 
exposure of mouse β-cells (MIN6) to high glucose levels resulted in differential expression of 
a large number of miRNAs. Among these, miR-124a, miR-30d and miR-107 were 
upregulated, while miR-296, miR-484 and miR-690 were downregulated by high glucose 
treatment of MIN6 cells (Tang et al., 2009).  
 
Furthermore, several human studies have demonstrated that miRNAs are differentially 
expressed in multiple tissue types, and are able to regulate the expression of multiple genes 
in a signaling cascade. MiRNAs are expressed in several tissues that play a crucial role in 
insulin signaling, glucose metabolism and β-cell development. Among others, miRNAs 
expressed in pancreatic tissue include miR-375, miR-29a, miR-96, miR-124a, miR-376 and 
let-7, while three of these miRNAs (miR-29a, miR-375, and miR-96) are also expressed in 
other tissue types, such as muscle, liver and adipose, and regulate the expression of 
multiple genes involved in maintaining glucose homeostasis. Studies have reported that 
these miRNAs exert their action on different tissue types, and present a consistent 
regulatory role during the pathogenesis of T2D (Zhu and Leung, 2015). Although miRNA 
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research has skyrocketed over the last few years (Friedlander et al., 2014), more studies are 
needed to improve the understanding of these miRNAs and their regulation during disease.  
1.9.4 Circulating microRNAs 
Majority of miRNAs are found intracellularly, while a significant number of miRNAs are found 
in the extracellular fluid outside the cell, and are particularly useful in biomarker discovery 
(Creemers et al., 2012; Hanson et al., 2009; Weber et al., 2010). These extracellular 
miRNAs circulate in the bloodstream and compared to mRNA levels, have been found to be 
remarkably stable among individuals of the same species (Chen et al., 2008; Hunter et al., 
2008). Circulating miRNAs are able to withstand unfavorable physiological conditions such 
as extreme pH variability, boiling, multiple freeze thaw cycles and extended storage, making 
them attractive, potential biomarkers for clinical research (Chen et al., 2008).  
 
It has been postulated, that the stability of these miRNAs may result from the formation of 
complexes between circulating miRNAs and specific proteins (Turchinovich et al., 2012).  
These complexes include ribonucleoproteins (RBP) such as argonaute (Ago1-4) or 
nucleophosphin 1 (NPM1), exosomes, apoptotic bodies, microvesicles and lipoprotein 
complexes which serve to protect these miRNAs from nuclease degradation, and act as 
carriers to transport them to their target mRNAs (Creemers et al., 2012) (Fig. 1.7). This 
suggests cell-to-cell communication, allowing miRNAs to influence gene expression in 
neighbouring cells when conditions become stressful (Creemers et al., 2012). MiRNAs 
encapsulated in microvesicles (made up of exosomes and shedding vesicles) are released 
from the cell through blebbing (protrusion or bulge) of the plasma membrane, and can then 
be transferred to recipient cells where they trigger functional effects and modulate gene 
expression (Hunter et al., 2008; Thery et al., 2002; Valadi et al., 2007).  
 
The release of exosomes and microvesicles from cells are regulated by sphingomyelin, a 
major lipid in the lipid bilayer of the cell membrane. The biosynthesis of sphigomyelin is 
tightly controlled by neutral sphingolimyelinase 2, a hydrolase enzyme involved in lipid 
metabolism, and ceramide, a component of sphingomyelin, dependent secretary-machinery 
in response to cellular stresses (Cortez et al., 2011; Kosaka et al., 2010; Trajkovic et al., 
2008). Some miRNAs are found in apoptotic bodies and are released as byproducts from 
cells into the extracellular compartment during apoptosis. This could partly explain the 
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presence of tissue specific miRNAs in blood after toxicity in certain tissues (Laterza et al., 
2009; Zhang et al., 2010). The majority (approximately 90-99%) of all circulating miRNAs 
appears to be vesicle-free, and is associated with RNA-binding proteins (eg. Ago, NPM1), 
which allow miRNAs to remain highly stable during extracellular circulation (Arroyo et al., 
2011; Turchinovich et al., 2011). Additionally, a small portion of circulating miRNAs has also 
been found to be associated with high density lipoproteins (HDL) (Wagner et al., 2013). High 
density lipoproteins are capable of delivering both exogenous and endogenous miRNAs to 
recipient cells, and mediating direct targeting of mRNA, which leads to gene expression 
alterations (Vickers et al., 2011). However, in contrast to exosomes, miRNA associated 
lipoproteins are negatively regulated by neutral sphingolimyelinase 2, and delivery is 
dependent on the cell surface HDL receptors (SR-B1) (Chen et al., 2012; Vickers et al., 
2011).  
 
Although the mechanism of action for cell-to-cell communication is not completely 
understood, two theories currently exist regarding the export and biological function of 
extracellular miRNAs. One theory suggests that miRNAs are merely byproducts of 
microvesicle secretion and cell death, while the other theory suggests that miRNAs are 
specifically secreted and function in intercellular communication via paracrine and even 
endocrine signaling routes (Turchinovich et al., 2012; Valadi et al., 2007; Cortez et al., 
2011).  
Figure 1.7 Circulating miRNAs and associated complexes, such as ribonuclear proteins (RBP), 
apoptotic bodies, microvesicles, exosomes and high density lipoproteins (HDL), found in the 
bloodstream (Adapted from Kinet et al., 2013).  
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1.9.5 Circulating microRNAs as clinical biomarkers for 
Type 2 diabetes 
Regardless of the mechanism regulating circulating miRNAs, recent studies suggest that 
different pathophysiological conditions cause inappropriate release of miRNAs into the 
blood, altering miRNA expression profiles, and mediating the repression of critical mRNA 
targets in recipient cells. This leads to altered gene expression levels that consequently 
cause metabolic dysregulation (Chen et al., 2012; Santovito et al., 2014). Thus, distinct 
modification in the miRNA profile in blood may reflect the development of various chronic 
diseases that can be detected several years before the disease and its complications 
manifests (Hydbring and Badalian-Very, 2013). Extracellular circulating miRNAs have 
signatures for various diseases, and could play a major role as potential biomarkers in health 
and disease (Chen et al., 2008). The first link between circulating miRNAs and disease 
came from cancer studies in 2008 (Gilad et al., 2008; Lawrie et al., 2008; Mitchell et al., 
2008). These studies showed that tumour-derived miRNAs, were detected in serum or 
plasma, and could distinguish between cancer patients and healthy individuals (Lawrie et al., 
2008; Mitchell et al., 2008). Subsequent studies have also showed that circulating miRNAs 
can identify and monitor the progression of CVD, liver injury and kidney disease (Ding et al., 
2012; Saal and Harvey, 2009; Van Rooij and Olson, 2012). These findings support the 
hypothesis that circulating miRNAs may be used as informative biomarkers to assess an 
individual‟s pathophysiological status, sparking interest in their use as high risk, diagnostic or 
prognostic biomarkers for disease.  
 
In light of the positive associations between miRNAs and disease, a number of studies are 
exploring circulating miRNAs for their diagnostic and prognostic ability in T2D (Pescador et 
al., 2013; Yang et al., 2014; Zhang et al., 2013). Indeed, a number of studies have shown 
that miRNAs that are dysregulated during glycaemia, can be present in whole blood, 
PBMCs, serum and plasma of diabetic, pre-diabetic and normo-glycaemic individuals (Table 
1.2).  
 
Studies have also investigated their mechanism of action, confirming their role in T2D 
pathogenesis. For example, Yan et al. (2014) showed that miR-199, a miRNA significantly 
upregulated in the plasma of T2D patients compared to normo-glycaemic individuals, binds 
to GLUT4 mRNA and represses its expression, and subsequently glucose uptake in L6 rat 
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myoblast cells (Yan et al., 2014). The expression of MiR-144, another miRNA upregulated in 
T2D patients compared to normo-glycaemic individuals was upregulated in rat islets cultured 
under hyperglycaemic conditions (Karolina et al., 2011). Furthermore, using the Dual 
Luciferase reporter assay and Western blot analysis, these authors showed that miR-144 
induces repression of insulin receptor substrate 1 (IRS1) mRNA and protein, demonstrating 
its potential role in the insulin signaling pathway (Karolina et al., 2011). Studies have shown 
that two T2D-associated miRNAs, miR-146a and miR-155, may mediate their pathogenic 
effects by stimulating inflammation (Balasubramanyam et al., 2011; El-Ekiaby et al., 2012; 
O'Connell et al., 2010; Taganov et al., 2006; Zhang et al., 2010). The expression of these 
miRNAs was negatively associated with inflammation (nuclear factor kB (NFkB) mRNA 
levels and circulatory levels of tumour necrosis factor alpha (TNFα), and interleukin (IL-1β 
and IL-1)). 
 
Interestingly, a number of studies have reported that circulating miRNAs can distinguish 
between T2D, pre-diabetes and normo-glycaemia. For example, according to Karolina et al. 
(2011), eight circulating miRNAs (miR-144, miR-146a, miR- 150, miR-182, miR-192, miR-
29a, miR-30d and miR-320) were shown to be differentially expressed in PBMCs, and could 
serve as potential signatures to distinguish between IFG and T2D. Furthermore, Parrizas et 
al. (2014) showed that circulating levels of miR-192 and miR-193b were significantly 
upregulated in pre-diabetic compared to normo-glycaemic individuals, and interestingly, the 
increased levels of these miRNAs in pre-diabetics reverted back to normal following a 
therapeutic exercise intervention. Moreover, the authors showed that the abundance of 
these miRNAs was significantly correlated with metabolic parameters including OGTT, 
triglycerides and fatty liver index (Parrizas et al., 2014). Similarly, Liu et al. (2014) showed 
that the decreased expression of miR-126 in pre-diabetic and diabetic individuals compared 
to normo-glycaemic individuals was returned to normal after glucose lowering treatment (Lui 
et al., 2014). Moreover, Yang et al. (2014) explored the clinical significance of serum 
miRNAs (miR-23a, let-7i, miR-486, miR-96, miR-186, miR-191, miR-192, and miR-146a) in 
T2D patients. Of these miRNAs, miR-23a had significantly lower expression according to 
disease progression, i.e.  diabetic < pre-diabetic < normo-glycaemic individuals (Yang et al., 
2014). Finally, a prospective, longitudinal study showed that the expression of five miRNAs, 
miR-15a, miR-29b, miR-126, miR-223 and miR-28-3p, changed in normo-glyceamic 
individuals during disease progression to T2D (Zampetaki et al., 2010). Altered miRNA 
expression profiles were observed upon the manifestation of T2D, over a period of ten years.  
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Together, these studies support the hypothesis that circulating miRNAs could help to 
distinguish normo-glycaemic from diabetic and pre-diabetic individuals, and may have the 
potential as early predictive biomarkers of T2D.
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Table 1.2 A summary of studies on circulating miRNAs in T2D (Adapted from Raffort et al., 2015) 
MicroRNA Sample Disease Summary Reference 
miR-20b, -21,-24, -15a, -126, -191, -
97, -223, -320, -486, -28-3p 
Plasma T2D Differential miRNA expression between T2D 
patients and normo-glycaemic individuals 
(Zampetaki et al., 2010) 
miR-15a, -29b, -126, -223, -28-3p Plasma T2D Differential miRNA expression during disease 
progression 
 
miR-126  Plasma T2D Differential miRNA expression between T2D 
normo-glycaemic individuals, and between T2D 
susceptible and normo-glycaemic individuals  
(Zhang et al., 2015) 
miR-146a Plasma T2D Differential miRNA expression between T2D 
patients and normo-glycaemic individuals 
(Rong et al., 2013)  
miR-24, -29b Plasma T2D Differential miRNA expression between T2D 
patients and  normo-glycaemic individuals 
(Wang et al., 2014) 
miR-144 Plasma T2D Dysregulation associated with T2D in Swedish 
people, not in Iraqi people 
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miR-375 Plasma T2D Differential miRNA expression between Kazak 
T2D and Han T2D, and differences in the 
methylation of promoter regions 
(Chang et al., 2014) 
miR-140-5p, -142-3p, -222,-423-5p, 
-125b, -192, -195, -130b, -532-5p, -
126 
Plasma T2D Differential miRNA expression between T2D 
patients and normo-glycaemic individuals 
(Ortega et al., 2014) 
miR-192, 140-5p, 222 Plasma T2D Modification of miRNA expression by metformin  
miR-222, 140-5p Plasma T2D Modification of miRNA expression by 
molecules inducing IR 
 
miR-375 Plasma T2D Differential miRNA expression between T2D 
patients and normo-glycaemic individuals 
(Sun et al., 2014a) 
miR-191, -200b Plasma T2D Differential miRNA expression between T2D 
and normo-glycaemic individuals; and a 
correlation between miRNAs and C-reactive 
protein and cytokine levels in T2D patients 
(Dangwal et al., 2015) 
miR-199 Plasma T2D Differential miRNA expression between T2D 
patients and normo-glycaemic individuals 
(Yan et al., 2014) 
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miR-326, -let-7a, -let-7f Plasma T2D Differential miRNA expression between T2D 
patients and normo-glycaemic individuals 
(Santovito et al., 2014) 
miR-9, -29a, -30d, -34a, -124a, 
-146a, -375 
Serum  T2D Differential miRNA expression between T2D 
patients and normo-glycaemic individuals; No 
significant difference in miRNA expression 
between pre-diabetic and normal glucose 
tolerance group 
(Kong et al., 2011) 
miR-126 Serum T2D Differential miRNA expression between T2D 
patients and normo-glycaemic individuals; 
Differential miRNA expression between pre-
diabetic patients and normo-glycaemic  
individuals; Modification of miRNA expression 
by glucose lowering treatment 
(Liu et al., 2014) 
miR-23a, -let-7i, -486, -96, -186, -
191, -192, -146a 
miR-23a 
Serum T2D Differential miRNA expression between T2D 
patients and normo-glycaemic individuals 
Differential miRNA expression between pre-
diabetic and normo-glycaemic individuals 
(Yang et al., 2014) 
miR-191, -139-5p, -21 
 
Serum T2D Differential miRNA expression between T2D 
patients and normo-glycaemic individuals 
(Parrizas et al., 2014) 
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miR-191, -15b, -128, -125a-5p, -50, 
-192, -193b 
Serum T2D Differential miRNA expression between pre-
diabetic and normo-glycaemic individuals 
(Parrizas et al., 2014) 
 
miR-192, -193b Serum T2D Differential miRNA expression in pre-diabetic 
but not in diabetic patients; Modification of 
miRNA expression by lifestyle intervention in 
pre-diabetics 
 
miR-138, -376a Serum T2D Differential miRNA expression between normo-
glycaemic individuals, diabetic and obese 
diabetic patients  
(Pescador et al., 2013) 
miR-let-7a Whole 
blood 
T2D Differential miRNA expression between T2D 
patients and normo-glycaemic individuals; 
Differential miRNA expression between T2D 
with diabetic nephropathy and T2D 
(Zhou et al., 2013) 
miR-144, -146a, -150, -182, -192, -
29a, -30d, -320 
PBMC T2D Differential expression between patients with 
IFG and T2D 
Karolina et al., 2011 
miR-146a, -155 PBMC T2D Differential miRNA expression between T2D 
patients and non-diabetic individuals; 
Correlation between miR-146a levels and 
fasting blood glucose, HbA1c and inflammatory 
signals 
(Balasubramanyam et al., 
2011) 
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miR-103b Platelets T2D Differential miRNA and gene target SFRP4 
expression between pre-diabetic, non-
complicated T2D, coronary heart disease T2D 
vs. healthy controls 
(Luo et al., 2015) 
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1.9.6 Techniques to study microRNA expression 
MiRNA research has been facilitated by technological advancement that has spawned a 
multitude of platforms which enabled large scale epigenomic studies. At present, techniques 
including quantitative real-time polymerase chain reaction (qRT-PCR), microarray 
hybridization techniques such as oligonucleotide arrays and in situ hybridisation, and high 
throughput sequencing (HTS) of miRNAs are popular and widely used profiling methods 
(Thomas and Ansel, 2010; Git et al., 2010; Pritchard et al., 2012; Meyer et al., 2010). Among 
these techniques, the most cost effective and frequently used method for miRNA profiling is 
qRT-PCR (Fu et al., 2006; Kroh et al., 2010). Quantitative RT-PCR is a highly reproducible, 
sensitive and specific method, which is used for quantifying miRNA expression levels. The 
target specificity is based on the design of primers and probes specific to the miRNA of 
interest (Benes and Castoldi, 2010). Furthermore, although more expensive, HTS allows 
global miRNA expression profiling for the detection of less abundant and novel miRNAs, 
which cannot be detected using qRT-PCR (Pritchard et al., 2012). 
1.10 Bioinformatics: messenger RNA target 
prediction analysis  
One of the most interesting aspects of miRNA biology is the ability of a single miRNA to 
regulate multiple genes involved in specific cellular mechanisms and signaling cascades (He 
and Hannon, 2004). Experimental techniques to identify miRNA targets include Luciferase 
reporter assays, Western blot analysis and Enzyme-linked immunosorbent assay (ELISA) or 
Immuno-cytochemistry experiments (Kuhn et al., 2008). The Luciferase reporter assay is a 
tool used to study gene expression at the transcriptional level, and can determine the direct 
binding ability of miRNAs on messenger RNA (mRNA) target sequence (Simon and Evin, 
2008). Studies have shown that miRNAs are able to regulate the expression of targets at the 
protein level (Selbach et al., 2008), thus, Western blot analysis, ELISA or Immuno-
cytochemistry present techniques used to study protein expression of miRNA targets at the 
translational level (Kuhn et al., 2008). However, these techniques are costly and time-
consuming, focusing attention towards computational miRNA:mRNA target prediction (Min 
and Yoon, 2010; Witkos et al., 2011). Bioinformatic analysis allows high-throughput target 
prediction, and is relatively easy to conduct. However, targets that were computationally 
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predicted, must be experimentally validated before they can be acknowledged as a miRNA 
target. 
  
The four most common miRNA:mRNA bioinformatics target prediction algorithms are based 
on seed match complementarity (Fig.1.6), sequence conservation, free energy and binding 
site structural accessibility (Kertesz et al., 2007; Lewis et al., 2003; Lewis et al., 2005; Oulas 
et al., 2015; Witkos et al., 2011). Although all these algorithms are critical for miRNA target 
prediction, their selection depends on the research question. Potential interactions are best 
identified by firstly using a program that considers seed match complementarity, since these 
are characterized by high sensitivity and precision. Thereafter, to increase specificity, 
additional features such as binding site structural accessibility and sequence conservation 
should be used (Witkos et al., 2011).   
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1.11 Study motivation 
The increasing prevalence of T2D globally places a huge financial and health burden on 
governments, particularly those in middle and low income countries (Whiting et al., 2011).  
Individuals with diabetes are highly vulnerable to a multitude of complications, including 
CVD, retinopathy, peripheral arterial disease and infectious diseases, which increase the 
cost to treat the disease (Zhuo et al., 2013). It is estimated that more than half of all people 
with diabetes, are unaware that they are living with the disease (IDF, 2013). Furthermore, 
the alarming increase of T2D in children and the high number of undiagnosed cases 
globally, suggests that T2D may become the world‟s greatest health challenge within the 
next 25 years.  
 
Although a multitude of tests are currently available to diagnose T2D, they are all based on 
blood glucose measurements, and are unable to identify individuals in the asymptomatic 
stage (pre-diabetic), when glucose levels are still normal. Thus, these individuals remain 
undetected for many years, and have an increased risk of developing long term metabolic 
complications. Furthermore, despite the array of tools available for the management of T2D 
(drug therapies, advanced technology and improved education), the potential benefit of 
these tools are lost in people with undiagnosed diabetes (Waugh et al., 2007).   
 
Several lines of evidence suggest that early intervention is the most effective strategy to 
reduce the prevalence of T2D, manage the disease, and to prevent complications. For 
example, diagnosis of T2D is associated with micro- and macro-vascular complications 
(Fowler, 2008; Vinik and Flemmer, 2002). Thus, the detection of individuals with sub-clinical 
disease, for example, during pre-diabetes may facilitate intervention strategies to prevent or 
delay the progression to disease, ultimately reducing mortality and morbidity.   
 
Research efforts to reduce the burden of T2D by early intervention and treatment are 
underpinned by the need for biomarkers to identify subclinical disease. Thus, the discovery 
of differentially expressed miRNAs between diabetic, pre-diabetic and normo-glycaemic 
individuals may have the potential as a pre-screening tool in high risk individuals. Moreover, 
identification of such miRNAs may provide insight into the pathophysiology of T2D and 
furthermore, may present novel therapeutic targets against diabetes.    
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1.11.1 Hypothesis 
We hypothesize that miRNA expression patterns are associated with the development of 
diabetes and that their expression profiles change during disease progression. The 
identification of different miRNA expression profiles in diabetic, pre-diabetic and normo-
glycaemic individuals could potentially represent early biomarkers for the development of 
T2D, and could facilitate intervention strategies to prevent, better manage or delay the 
development of T2D. 
1.11.2 Aim 
The aim of this study is to determine whether miRNA expression patterns differ in diabetic, 
pre-diabetic, and normo-glycaemic individuals, thereby offering the potential as biomarkers 
which could be used to identify individuals with a high risk of developing T2D. 
1.11.3 Objectives 
 Recruit subjects and obtain blood samples from diabetic, pre-diabetic and normo-
glycaemic individuals, 
 Measure metabolic parameters (FPG, OGTT, HbA1c, insulin, glucagon, C-peptides 
and lipid profile), 
 Characterize participants according to WHO classification using FPG, OGTT and 
HbA1c  test, 
 Match participants according to age, gender, ethnicity and BMI, 
 MiRNA expression profiling in PBMCs of diabetic, pre-diabetic and normo-glycaemic 
individuals using Illumina sequencing, 
 Validation of selected differentially expressed miRNAs in PBMCs of diabetic, pre-
diabetic and normo-glycaemic individuals by qRT-PCR, 
 Validate the selected miRNAs in serum of diabetic, pre-diabetic and normo-
glycaemic individuals by qRT-PCR, and 
 Bioinformatic analysis to assess functional significance of miRNAs and their mRNA 
targets. 
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2. MATERIALS AND METHODS 
2.1 Study design 
A flow diagram illustrating the experimental protocol is shown in Figure 2.1. Briefly, 258 
research participants were recruited to the study and were classified as diabetic (T2D), pre-
diabetic or normo-glycaemic (control) according to WHO criteria (WHO, 2006). The preferred 
criteria used in the South African setting. These participants were matched according to age, 
gender, ethnicity and body mass index (BMI), and four individuals per group were selected 
for this study. Thereafter, miRNAs were profiled in peripheral blood mononuclear cells 
(PBMCs) and in serum samples of these individuals using next generation sequencing and 
qRT-PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Study overview. 
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2.2 Subject recruitment  
Relatives and friends of individuals from diabetes support groups or high risk individuals 
recommended by medical practitioners in the Cape Town Metropole, South Africa were 
invited to partake in the study. Individuals were predominantly from Malmesbury, while 
others were from Parow and Mitchells Plain. The inclusion criteria of the study were: 1) 
subjects that were never diagnosed with T2D, 2) subjects that were a first-degree blood 
relative of someone previously diagnosed with T2D i.e. a parent, child or full sister/brother, 
and 3) subjects that were a second-degree relative of someone previously diagnosed with 
diabetes i.e. a grandparent, grandchild, aunt/uncle, nephew/nieces or half-brother/sister. The 
exclusion criteria of the study were: 1) subjects that were on any form of medication for 
health related issues. The study aims and procedures were explained to subjects in a 
language they understood (Appendix 1). Subjects were recruited to the study after they 
provided written informed consent confirming that they understood and agreed to participate 
in the study (Appendix 2). All procedures were conducted according to Ethical Guidelines for 
research in South Africa and approval for the study was granted by the ethics committee of 
the South African Medical Research Council (EC010-5/2013) and the Human Research 
Ethics Committee of Stellenbosch University (S15/04/095). All participants were required to 
complete a questionnaire, whereafter bodyweight, height and blood pressure was measured 
with a calibrated scale (UC-321S digital, A&D Medical, San Jose, California) portable  
stadiometer (Seca 214,  Seca GmbH & Co, Hamburg, Germany) and a blood pressure 
monitor (Omron, HiTech, Bryanston, South Africa), respectively. Staff who were involved in 
the study (conducted the interviews, anthropometric measurements and blood collection) 
were trained by the clinic site project manager at the start of the study.  
2.3 Blood collection 
Blood glucose concentrations were measured with a calibrated glucometer (OneTouch, 
Lifescan inc., Milpitas, California.) after an overnight fast of about 10 hours (hrs), using the 
second drop of blood obtained by finger prick. Thereafter, blood from the upper arm was 
collected by a trained nurse, phlebotomist or medical doctor.  Twelve tubes of blood were 
collected from each participant; eight fasting and four during the oral glucose tolerance test 
(OGTT). Eight fasting blood samples were collected in one fluoride-containing tube (to 
reduce glycolysis) to measure glucose concentrations, four gel-containing tubes (induce 
coagulation and for collection of serum) to measure insulin, c-peptide, and lipid 
concentrations, and to determine protein markers, one Ethylenediaminetetraacetic acid 
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(EDTA) tube for HbA1c and DNA extraction, one EDTA tube containing trasylol for glucagon 
measurement, and finally in a PAXgene tube for the isolation of miRNA.  Thereafter, 
subjects were required to drink 75 grams (g) of glucose in 100 ml of water, and blood was 
collected after 30 minutes (min) and 120 min in SST tubes and fluoride-containing tubes for 
measuring insulin and glucose concentrations. Samples were stored on ice, and were either 
sent to Pathcare (Pathcare, South Africa) or to the laboratory (BRIP, SAMRC) for processing 
using standard operating procedures. 
 
For serum collection, BD Vacutainer® SST™ Tubes (Vacutainer, BD, Woodlands, South 
Africa) were stored at room temperature for 2 hrs prior to centrifugation (5810R, Eppendorf, 
Hamburg, Germany) at 4 Celsius (oC) for 15 mins at 3220 g (relative centrifugal force). Each 
tube was coated with silicone and micronized silica particles to accelerate clotting of blood, 
and contains a gel that separates blood cells and plasma from serum. Once separated, the 
serum from each tube was aliquoted into cryotubes (250 µl) and stored at -80oC for long 
term storage (Fig. 2.2A). 
 
PAXgene® Blood RNA Tubes (PreAnalytix, Qiagen, Feldbachstrasse, Switzerland)  contain 
6.9 ml of RNA stabilising reagent that lyses peripheral blood mononuclear cells (PBMCs) 
and immediately stabilizes intracellular RNA by preventing in vitro RNA degradation and 
minimizing gene induction (Fig. 2.2B). Briefly, 2.5 ml of blood was collected into the tubes 
and processed according to the manufacturer‟s instructions. Tubes were gently inverted 10 
times immediately after blood collection, and thereafter stored upright at room temperature 
(20ºC to 25ºC) for 2 hrs, transferred to 4ºC for 24 hrs, -20°C for 24 hrs and finally transferred 
to -80ºC for long-term storage upright in wire or metal racks.  
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Figure 2.2 An illustration of A) BD vacutainer tubes and B) PAXgene blood RNA tubes for collecting 
blood. 
 
2.4 Selection of subjects for microRNA profiling 
Subjects were characterized as diabetic, pre-diabetic and normo-glycaemic individuals 
based on their OGTT, FPG and HbA1c concentrations, according to the WHO diagnostic 
classification criteria (Fig. 2.3, WHO, 2006). Subjects with OGTT, FPG and HbA1c levels 
≥11.0 mmol/L, ≥7.0 mmol/L and ≥6.5 %, respectively, were classified as diabetic, while 
subjects with OGTT and FPG levels between 7.8 mmol/L-10.9 mmol/L and 6.1 mmol/L-6.9 
mmol/L, respectively, were classified as pre-diabetic. Furthermore, subjects with OGTT and 
FPG levels <7.8 mmol/L and <6.1 mmol/L, respectively, were characterized as normo-
glycaemic individuals. Thereafter, subjects in each group were matched according to age, 
gender, ethnicity and BMI for miRNA profiling of their blood samples. 
  
A B
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Figure 2.3 WHO criteria for classification of diabetic, pre-diabetic and normo-glycaemic (WHO, 2006). 
 
2.5 RNA isolation and quantification:  
RNA was isolated from the PBMCs and serum of diabetic, pre-diabetic and normo-glycaemic 
individuals, using the PAXgene blood miRNA kit (Qiagen, Hilden, Germany), and the 
miRNeasy Serum/Plasma kit (Qiagen, Hilden, Germany) respectively. 
2.5.1 Peripheral blood mononuclear cells 
PAXgene® Blood RNA tubes were thawed gradually according to the manufacturer‟s 
recommendations. Briefly, tubes were removed from -80°C and allowed to thaw by 
transferring them to -20°C for 24 hrs and thereafter to room temperature (20°C - 25°C) for 2 
hrs. Once thawed, tubes were inverted 10 times whereafter RNA extraction was conducted 
using the PAXgene blood miRNA kit according to the manufacturer‟s instructions. Peripheral 
blood mononuclear cells were pelleted by centrifuging PAXgene blood RNA tubes at 3220 g 
for 10 mins using a swing-out rotor (5810R, Eppendorf, Hamburg, Germany). Thereafter, 
cells were washed with 4 ml of RNAse free water, vortexed for 10 seconds (s) until the pellet 
Oral glucose tolerance test (mmol/L)
Fasting plasma glucose test (mmol/L)
HbA1c (%)
<7.8 7.8-10.9 ≥11.0
<6.1 6.1-6.9 ≥7.0
Not specified Not specified ≥6.5
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was visibly dissolved, and re-centrifuged at 3220 g for 10 mins. The supernatant was 
removed by decanting and inverting the tube, the cell pellet was resuspended in 350 µl of 
buffer BM1 and vortexed for 10 mins until the pellet was visibly dissolved. Thereafter, 
samples were digested by adding 300 µl of buffer BM2 and 40 µl of proteinase K (20 mg/ml), 
vortexed for 5 s and incubated for 10 mins at 55°C in a shaking incubator at 1400 
revolutions per minute (rpm) (Qiagen, Retsch, Germany).  
 
After incubation, samples were homogenized by pipetting, transferred onto a PAXgene 
Shredder spin column in a 2 ml tube, and centrifuged for 3 mins at full speed (16100 g) 
(5415R, Eppendorf, Hamburg, Germany). Supernatants were transferred into new tubes, 
700 µl of isoproponol was added and samples were mixed vigorously by vortexing. 
Thereafter, 700 µl of sample was pipetted onto a PAXgene spin column in a 2 ml tube, and 
centrifuged at 16100 g for 1 min. The spin column was placed in a new 2 ml tube, and the 
remaining sample pipetted into the PAXgene spin column, and centrifuged at 16100 g for 1 
min. Thereafter, 350 µl of buffer BM3 was added to the spin column and centrifuged at 
16100 g for 15 s. RNA was then subjected to on-column DNase digestion by pipetting 80 µl 
of DNase I incubation mix (10 µl DNase 1 stock solution added to 70 µl buffer RDD) directly 
onto the PAXgene spin column membrane, and incubating at room temperature (20°C - 
25°C) for 15 mins. Samples were washed by adding 350 µl and 500 µl of buffer BM3 and 
BM4, respectively, to the spin columns, and centrifuged at 16100 g for 15 s, while discarding 
the flow through each time. Another 500 µl of buffer BM4 was added to the PAXgene spin 
column, and centrifuged at 16100 g for 2 mins. The PAXgene RNA spin column was placed 
in a new 2 ml tube, and centrifuged at 16100 g for 1 min to completely dry the spin column 
membrane. Thereafter, 40 µl of elution buffer BR5 was directly pipetted onto the spin column 
membrane, and centrifuged at 16100 g for 1 min to elute the RNA. RNA was denatured by 
incubating at 65oC for 5 mins and immediately chilling it on ice.  
 
RNA concentrations were determined by measuring the absorbance at a wavelength of 260 
nm (A260) using a nanodrop spectrophotometer (Nanodrop Technologies, Wilmington, USA). 
RNA purity was assessed by using the A260/280 (protein contamination) and A260/230 (salt 
contamination) ratios, where a ratio of 1.8 - 2 indicates a high level of purity and is assumed 
suitable for gene expression measurements.  
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2.5.2 Serum 
Frozen serum aliquots in cryotubes were removed from -80oC and allowed to thaw by 
incubating at 37oC in a water bath for 3 mins. Once samples were thawed, miRNA-enriched 
total RNA was extracted from 200 µl of serum using the miRNeasy Serum/Plasma kit, 
according to the manufacturer‟s instructions. One thousand microliters of QIAzol lysis 
reagent was added to each serum sample, mixed by vortexing for 5 s, and left on the 
benchtop at room temperature (15oC - 25oC) for 5 mins. Thereafter, 3.5 µl of MiRNeasy 
serum/plasma spike-in-control (Caenorhabiditis elegans-miR-39) (1.6 x 108 copies/µl 
working solution) was added as an exogenous synthetic miRNA to control for technical 
variation during RNA extraction, cDNA synthesis and qRT-PCR processing. Two hundred 
microliters of chloroform was then added to each sample and vortexed for 15 s for 
subsequent phase separation. Samples were left on the benchtop at room temperature 
(15oC - 25oC) for 2 to 3 mins, and then centrifuged (5415R, Eppendorf, Hamburg, Germany) 
at 4oC for 15 mins at 16100 g. After centrifugation, the upper colourless aqueous phase 
containing approximately 600 µl of RNA was transferred to a new collection tube, and mixed 
thoroughly with 900 µl of 100% ethanol. Thereafter, 700 µl of sample was pipetted into an 
RNeasy MinElute spin column, and centrifuged at 11200 g for 15 s at room temperature 
(15oC - 25oC). This step was repeated, and the flow through was discarded both times. 
Samples were then washed with 700 µl and 500 µl of buffer RWT and RPE, respectively, 
and centrifuged at 11200 g for 15 s. For a final wash, 500 µl of 80% ethanol was added into 
the RNeasy MinElute spin column, and centrifuged for 2 mins at 11200 g at room 
temperature (15oC - 25oC). The spin column was placed in a new 2 ml processing tube, and 
centrifuged at 16100 g for 5 mins to completely dry the spin column membrane. After drying, 
the spin column was placed in a 1.5 ml tube, and 14 µl of RNase-free water was directly 
pipetted onto the spin column membrane, and centrifuged at 16100 g for 1 min to elute the 
RNA. 
 
Total RNA concentration was measured using a nanodrop spectrophotometer (Nanodrop 
Technologies, Wilmington, USA) as mentioned previously. 
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2.6 Assessment of RNA integrity  
RNA quality is known to affect the efficiency and accuracy of downstream experiments and 
high quality RNA is essential to obtain reliable gene expression data (Fleige and Pfaffl, 
2006). In mammalians, the 28S/18S ratio is used to assess RNA integrity, where a ratio of 
2:1 is generally representative of good quality RNA, and is considered optimal for 
downstream applications (Wieczorek et al., 2012). RNA quality has historically been 
assessed using agarose or acrylamide gel electrophoresis to quantitatively and qualitatively 
measure RNA concentrations. However, newer methods such as the Agilent 2100 
bioanalyser (Agilent Technologies, CA, USA) have revolutionized RNA integrity 
determination since they require less RNA sample and time. The bioanalyser is an 
automated device, utilizing microfluidic technology to analyze the quality of RNA on a 
sample-specific chip, using only 1 µl of RNA sample. The analysis can be completed in 
approximately 30 to 40 mins.  
2.6.1 Total RNA 
To assess the quality of the total RNA extracted using the PAXgene blood miRNA kit, the 
Agilent RNA 6000 Nano kit (Agilent Technologies, CA, USA) was used, according to the 
manufacturer‟s instructions. Firstly, 9 µl of fluorescent gel-dye mixture was pipetted into the 
nanochip, and primed using a plunger to form micro-channels consisting of interconnected 
networks (Fig. 2.4A). The plunger was held down for exactly 30 s before releasing the clip, 
and then slowly pulled back to the 1 ml position after 5 s. Another 9 µl gel-dye mixture was 
added to a different well in the nanochip. For calibration, 5 µl of RNA marker was added into 
all the sample wells, as well as to the RNA ladder well, which was included as a positive 
control to align all plots. The samples and RNA ladder were denatured for 2 mins at 70oC 
and loaded into individual wells of the chip. Thereafter the chip was vortexed at 1000 rpm for 
1 min (Fig. 2.4B), and immediately loaded onto the Agilent 2100 Bioanalyser (Fig. 2.4C) 
.  
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Figure 2.4 Representative image of an Agilent LabChip assay with A) priming station and plunger, B) 
the vortex used for the Agilent chip, and C) an Agilent 2100 Bioanalyser used to determined RNA 
quality. 
 
In the bioanalyser, 16-pin electrodes are arranged to fit perfectly into each well of the chip 
and are connected to an independent power supply that provides maximum control and 
flexibility. Charged RNA biomolecules are electrophoretically driven by a voltage gradient of 
constant mass-to-charge ratio that separates these molecules according to size in the 
presence of the sieving polymer matrix. During the chip run, the dye intercalates directly with 
the RNA, and is detected via laser-induced fluorescence detection. The amount of measured 
fluorescence correlates directly with the amount of RNA of a given size (Mariam Ayabi, 
2007). A RNA ladder containing a range of different size fragments is used as a reference 
for data analysis. The data is then visualized as an electropherogram (Fig. 2.5A), or 
translated into a virtual gel image (Fig.  2.5B). The 28S:18S ribosomal ratio is calculated by 
assessing the bands or peaks of each sample, and represents the quality of the RNA. The 
integrity of each sample is represented by an RNA integrity number (RIN) ranging between 1 
and 10, where 10 represents high quality intact RNA and 1 represents a completely 
degraded RNA sample (Mueller et al., 2004). All samples with a RIN greater than 7 were 
used in this study. 
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 2 MATERIALS AND METHODS 
43 
 
Figure 2.5 Example of a bioanalyser electropherogram and a virtual gel image detailing the regions 
that are indicative of good quality RNA. A) An electropherogram illustrating peaks representing 
variable rRNA sizes. B) A virtual gel illustrating two clear ribosomal bands illustrating 28S and 18S, 
with a RIN of 10 (Adapted from Mueller et al. 2004). 
 
2.6.2 MicroRNA  
MiRNAs are a unique class of small sized nucleic acids that can be accurately examined 
with the same technologies as total RNA. MicroRNA quality and its percentage relative to 
total RNA, was assessed using the Agilent small RNA (Pico) kit (Agilent Technologies, CA, 
USA), according to manufacturer‟s instructions. This kit enables the detection and analysis 
of small RNAs (<200 nt) and miRNAs (15 - 40 nt) within a small RNA fraction (Fig. 2.6). The 
concentration of miRNA is calculated as an absolute amount (pg/µl) and as a percentage 
(%) of small RNA in the total RNA sample. Briefly, the same procedures for miRNA analysis 
was followed as described previously for total RNA (section 2.6.1), except that: 1) the 
plunger in the priming station (which forms micro-channels) was held down for 60 s instead 
of 30 s and 2) the syringe clip was adjusted from the highest to the lowest position. 
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Figure 2.6 Representative image of an electropherogram for small RNA analysis, showing the content 
of small RNAs (miRNAs, tRNAs, and small rRNAs) that form part of the total RNA sample (Adapted 
from: Agilent Technologies, 2007). 
 
2.7 MicroRNA sequencing 
To gain insight into miRNA regulation during T2D progression, miRNAs were isolated from 
PBMCs of diabetic, pre-diabetic and normo-glycaemic individuals and subjected to high 
throughput miRNA sequencing (Arraystar, Rockville, USA). MiRNA sequencing has a wide 
dynamic range and is a highly sensitive and accurate technique that can distinguish between 
very similar miRNA sequences and isoforms, and is able to discover novel uncharacterized 
miRNAs (Motameny et al., 2010). 
 
Approximately 2 µg of RNA from age, gender, BMI and ethnicity matched diabetic (n=4), pre-
diabetic (n=4) and normo-glycaemic individuals (n=4) were lyophilized by freeze-drying 
according to the manufacturer‟s instructions (VirTis Benchtop K, United Scientific), using 100 
mTorr optimum vacuum pressure at -113oC (condenser temperature) for approximately 90 
mins. Thereafter, samples were stored at -80oC for 24 hrs until shipping on dry ice to the 
USA, as recommended by Arraystar. MicroRNA sequencing was performed on an Illumina 
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Hiseq 2000 instrument (Illumina Inc., San Diego, USA), using TruSeq Rapid SBS kits 
(Illumina), according to the manufacturer‟s instructions. The procedures followed by 
Arraystar are described below. 
  
Firstly, lyophilized samples were resuspended in water, and the concentrations of the RNA 
samples were measured using the NanoDrop ND-1000 instrument. The A260/A280 ratios were 
used to assess purity, and each sample was subjected to miRNA sequencing. A miRNA 
sequencing library was prepared as follows: firstly, total RNA was subjected to 
polyacrylamide gel electrophoresis and bands corresponding to the size of the miRNAs (~15 
- 35 nt) were excised from the gel for further processing (Fig. 2.7B). Thereafter, 3‟ and 5‟ 
small RNA adapters were sequentially ligated to the size selected RNA molecules, using T4 
RNA ligase 2 (Fig. 2.7C). Adapters act as binding sites for primers, allowing reverse 
transcription and complementary DNA (cDNA) synthesis to form a cDNA library. Thereafter, 
the cDNA library was run on a polyacrylamide gel, and the band corresponding to the 
molecular size of miRNA fragments with ligated adapters (~135 - 155 bp) was excised from 
the gel for subsequent sequencing (Fig. 2.7D). The cDNA libraries were quantified by the 
Agilent 2100 Bioanalyser, using the Agilent DNA 1000 chip kit (Agilent Technologies), and 
denatured with 0.1M NaOH. The samples were diluted to a final concentration of 8 pM and 
cluster generation was performed on the Illumina cBot using the TruSeq Rapid SR cluster 
kit, according to manufacturer‟s instructions. Single stranded DNA molecules were captured 
on Illumina flow cells, amplified in situ as clusters and sequenced for 36 cycles on the 
Illumina Hiseq 2000, according to the manufacturer‟s instructions. Several basic data 
processing steps were then performed to extract the relevant information from the raw data 
as described below.  
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Figure 2.7 A Schematic representation of the miRNA sequencing procedure (Adapted from 
Motameny et al. 2010). 
 
The raw data (also called reads) were generated by aligning the sequences of expressed 
miRNAs to the reference human genome in miRBase version (v) 21, to produce clean reads. 
Clean reads were provided as text files in FASTQ format as illustrated in Figure 2.8. These 
files contain four lines per read: the first line is the title line which contains the „@‟ symbol, 
followed by a (unique) read identifier; the second line contains the read‟s nucleotide 
sequence; the third line contains the read identifier again, preceded by a „+‟ symbol to signal 
the start of the quality string and the end of the sequence lines; and the fourth line contains 
A
B
C
D
E
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quality encoding scores (Cock et al., 2010). The missing nucleotides in the read sequence 
were denoted with an „N‟ character, underlined in red (Fig. 2.8). All sequence reads start at 
the first base after the 5‟ sequence adapter, and typically ends after 36 bp, thus excluding 
the 5‟ adapter sequence from the reads. However, all reads contained part of the 3‟ adapter 
sequence, and to eliminate ambiguity of sequence detection, these 3‟ adapter sequences 
were removed from the mature miRNA sequence (trimmed reads). Trimmed reads were 
recorded in FASTA format. 
Figure 2.8 An extract of the sequence data in FASTQ format illustrating the four lines per read. 
 
All trimmed reads greater than or equal to 15 nt in length, with zero or one base pair 
mismatch were aligned to the reference human genome in mirBase, to identify known 
miRNAs from previously annotated miRNAs, using Novoalign software, v2.07.11. All other 
reads were discarded, and the alignment results were saved in text files. The miRNA 
isoforms with the highest read counts were used to estimate the expression levels of each 
miRNA. The expression of each unique sequence (s) occurring among the reads in the 
sample were normalised (as reads per million) against the total number of reads produced 
for the sample, to estimate the relative expression level of each miRNA (Equation 2.1) 
(Motameny et al. 2010), and to compare expression patterns between groups (normo-
glycaemic vs. pre-diabetic; normo-glycaemic vs. diabetic and pre-diabetic vs. diabetic). 
Significantly differentially expressed miRNAs were classified as those having fold changes 
(FC)  1.1 and p-values  0.05 (threshold values set by ArrayStar). Furthermore, novel 
miRNAs were predicted from the miRNA sequencing data using miRDeep algorithms. This 
uses a score compatibility model of the position and frequency of the mature miRNA 
sequence with the secondary structure of the miRNA precursor (Friedlander et al., 2008). 
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Equation 2.1 Calculation used to determine reads in each sample. 
 
2.8 Quantitative real time PCR  
Quantitative real-time PCR (qRT-PCR) is a sensitive, accurate and reliable method to 
measure miRNA expression, and is often used to validate miRNA sequencing data. This 
method enables the detection and measurement of the exact amount (relative or 
quantitative) of DNA or RNA product, by determining the number of copies of DNA or RNA in 
each sample.  When RNA is used as a template, reverse transcription before amplification of 
the mRNA is necessary in order to quantify gene expression (Livak and Schimittgen, 2001).  
2.8.1 Reverse transcription 
Reverse transcription refers to the process whereby miRNA is reverse transcribed into 
cDNA, using reverse transcriptase. The cDNA is then used as a template for exponential 
amplification, using PCR. In this study, the TaqMan® MicroRNA Reverse Transcription (RT) 
kit (Life Technologies, Carlsbad, USA) and the miScript II RT kit (Qiagen, Hilden, Germany) 
were used, according to the manufacturer‟s instructions. The Taqman RT kit uses highly 
stable, small miRNA-specific stem-loop RT primers which lengthen the target cDNA, thus 
reverse transcribing mature miRNAs. On the other hand, the miScript II RT kit uses random 
hexamers or oligo-(dT) primers that randomly binds to and reverse transcribes large 
fragments of mRNA, to form cDNA.  
2.8.2 PCR 
The two most common technologies for the detection of PCR products in qRT-PCR are 
Taqman probes and SYBR Green. Taqman probes are sequence specific oligonucleotides 
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that are labelled with a fluorescent reporter, such as FAMTM and a non-fluorescent quencher 
(NFQ), which is covalently attached to the 5‟ and 3‟ end of the probe, respectively. When the 
fluorescent reporter dye and quencher molecule are in close proximity, emission of the 
reporter dye is prevented. Furthermore, Taq polymerase extends the amplicon, making new 
complementary DNA before it reaches the 5‟ end of the TaqMan probe, where upon the 5‟- 
3‟ exonuclease activity of Taq polymerase hydrolyses the probe base by base releasing the 
fluorescent reporter dye. Once the fluorescent reporter dye and quencher dye are no longer 
in close proximity, fluorescence is emitted and a signal is collected (Benes and Castoldi, 
2010).  
 
Using specific optical system software, fluorescence is measured at each cycle for each 
product and the signal is collected at a specific cycle threshold (Ct) on the Applied Biosystem 
7500 instrument (Thermo ScientificTM, MA, USA). The fluorescence is directly proportional to 
the amount of PCR product generated, and therefore permits a specific, quantitative 
measure of miRNA expression levels in each sample. SYBR Green is a fluorescent dye that 
intercalates with any double-stranded DNA resulting in light emission. SYBR green I dye will 
detect all double-stranded cDNA, including non-specific reaction products, while Taqman 
probes detects only specific amplification products (Bustin and Mueller 2005). 
2.8.2.1 Taqman probes 
MiRNA sequencing data was validated using Taqman probes. Briefly, 10 ng of miRNA-
enriched total RNA was reverse transcribed into cDNA with small RNA-specific, stem-loop 
RT primers specific to the microRNAs of interest (Table 2.1), and to custom designed 
primers for novel miRNA detection (Table 2.2), using the TaqMan® MicroRNA Reverse 
Transcription Kit according to the manufacturer‟s instructions. Thereafter, 15 µl of cDNA was 
amplified with TaqMan probes specific to the miRNAs of interest (Table 2.1 and 2.2), and 
TaqMan® Universal PCR Master Mix II.  
 
RNU6b, miR-454 and miR-425 were used as endogenous reference miRNAs (Table 2.1). 
Normfinder; a mathematical model of gene expression, that uses an algorithm to estimate 
overall  variation of reference genes and variation between subgroups of the same sample 
set was used to identify the best endogenous reference miRNA (Andersen et al. 2004). The 
delta delta Ct (2−ΔΔCT)  method was used to quantify relative expression using equation 2.2.  
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Equation 2.2 Calculation used to determine relative miRNA expression. 
 
Table 2.1 MiRNA primer and probe assays used for validation analysis. 
miR refers to the mature form of the miRNA, while the first three letters (hsa) signifies the organism 
(human in this case) that the miRNA is expressed in. The number following „miR‟ refers to the order in 
which they were discovered and published, and the 3p or 5p signifies the miRNA precursor arm 
(Wright and Bruford, 2011).  
#
NCBI miRNA accession number 
*Mature miRNA sequence selected from the sequencing data 
±
Mature miRNA sequence selected from Applied Biosystem‟s database  
Assay name miRbase ID/ 
NCBI acc. # 
Assay 
ID 
Species Mature microRNA sequence 
hsa-miR-27b hsa-miR-27b-3p 000409 Human UUCACAGUGGCUAAGUUCUGC*
±
 
hsa-miR-98 hsa-miR-98-5p 000577 Human UGAGGUAGUAAGUUGUAUUGUU*
±
 
hsa-miR-143 hsa-miR-143-3p 002249 Human UGAGAUGAAGCACUGUAGCUC*
±
 
hsa-miR-21 hsa-miR-21-3p 002438 Human CAACACCAGUCGAUGGGCUGU*
±
 
hsa-miR-379 hsa-miR-379-5p 001138 Human UGGUAGACUAUGGAACGUAGG*
±
 
hsa-miR-425 hsa-miR-425-5p 001516 Human AAUGACACGAUCACUCCCGUUGA
±
 
hsa-miR-454 hsa-miR-454-3p 002323 Human UAGUGCAAUAUUGCUUAUAGGGU
±
 
RNU6B NR_002752 # 001093 Human 
CGCAAGGAUGACACGCAAAUUCGU
GAAGCGUUCCAUAUUUUU
±
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Table 2.2 Custom designed primer and probe assays for validation of novel miRNAs. 
 
Assay 
name# 
 
Mature ID† 
 
Assay ID 
 
Species 
 
Mature miRNA sequence 
MYNO59 hsa-miR-novel-
chr6_11861 
CSCSU6 human UACUUGACCUUGACUCUCCCU
±
 
MYNO8 hsa-miR-novel-
chr9_17319 
CSD1TDE human AAGUUUCUCUGAACGUGUAGAGC
±
 
MYNO66 hsa-miR-novel-
chr22_33839 
CSGJPPU human GAUGCCUGGGAGUUGCGAUCUG
±
 
MYNO95 hsa-miR-novel-
chr12_22392 
CS39QZ3 human AAAGCAAAUGUUGGGUGAACGG
±
 
MYNO22 hsa-miR-novel-
chr15_25713 
CS5IO6B human UCCCUGUCCUCCAGGAGCU
±
 
#
Temporary primer assay name 
†
Mature novel miRNA ID illustrating its chromosomal location 
±
Mature sequence selected from sequencing data 
2.8.2.2 SYBR Green 
MiRNA detection in serum samples was conducted using the miScript PCR SYBR Green 
detection kit (Qiagen, Hilden, Germany) according to the manufacturer‟s instructions. Briefly, 
90 ng of total RNA in a 20 µl reaction was reverse transcribed into cDNA, using the miScript 
Hispec Buffer, nucleic acid and reverse transcriptase mix from the miScript II RT kit, 
according to the manufacturer‟s recommendations.  
 
Complimentary DNA was diluted with 200 µl of RNAse free water and 1 µl was used as a 
template for real-time PCR analysis, using miRNA-specific miScript primer assays (Table 
2.1) as forward primers and the miScript universal primer as the reverse primer and miScript 
SYBR Green PCR master mix, in a total volume of 10 µl. Relative expression was quantified 
using the 2−ΔΔCT method as described in section 2.8.2.1. 
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2.9 Messenger RNA target prediction analysis 
Bioinformatic target prediction analysis was performed to predict the mRNA targets of miR-
27b, miR-143, miR-98, miR-21 and miR-379. Messenger RNA targets are predicted 
according to seed match complementarity between mature miRNAs and the 3‟ untranslated 
region (UTR) of their mRNA target, sequence conservation, free energy and target site 
accessibility. Table 2.3 lists three mRNA target prediction programs (TargetScan-Human 
(TargetScan), Probability of Interaction by Target Accessibility (PITA) and DNA Intelligent 
Analysis (DIANA)-microT-CDS) that use different algorithms for target prediction (Fig. 2.9).  
 
The TargetScan algorithm integrates thermodynamic based modeling of miRNA:mRNA 
interaction and searches for perfect complementarity and sequence conservation to predict 
miRNA targets conserved across multiple genomes. Binding of the 6 nt miRNA seed region 
forms perfect base pairing complementarity to the 3‟ UTR target mRNA region, and then 
extends to binding long fragments outside the seed region to filter out false positives 
(Friedman et al., 2009; Lewis et al., 2005). Thus, defining the score for miRNA:mRNA target 
interactions includes features such as 3‟ complementary pairing, local adenine and uracil 
content and position contribution of miRNA:mRNA binding (Lewis et al., 2005; Grimson et 
al., 2007). Compared to TargetScan, the DIANA algorithm uses a much longer frame (38 nt) 
for scanning complementarity, and focuses on coding regions of target mRNAs to increase 
specificity and sensitivity (Min and Yoon, 2010). It also calculates the minimum binding 
energy between miRNAs and sequences in the mRNA 3‟ UTR target region, which 
generates a scoring system to help evaluate the significance of the predicted targets 
(Kiriakidou et al., 2004; Maragkakis et al., 2009). Additionally, DIANA allows mismatches 
and weak binding at the 5‟ seed region, involving six consecutively paired nucleotides within 
the seed region or guanine:uracil (G:U) wobble pairs if additional base pairing between the 
miRNA 3‟ end and target region exists (Min and Yoon, 2010). Furthermore, the PITA 
algorithm predicts targets based on free energy and target site accessibility, by calculating 
the free energy gained from the miRNA:mRNA duplex and the energy cost of unpairing the 
target to make it accessible to the miRNA (Witkos et al., 2011).  
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Table 2.3 Computational methods used for miRNA target prediction analysis. 
Target 
prediction 
Program 
Algorithm used for 
target prediction 
Advantages Disadvantages URL References 
 
TargetScan-
Human 
Seed match; 
Sequence conservation;  
3‟ complementarity; 
local AU content and 
position contribution 
 
Parameters including 
in target scoring; 
Final score correlates 
with protein 
downregulation 
Sites with poor 
seed paring are 
omitted 
http://targetscan.org/ (Lewis et al., 2005) 
 
DIANA-
microT-CDS 
Free energy binding 
and complementarity 
Signal-to-noise ratio 
and probability given 
to each target site-
possibility of using 
own miRNA sequence 
as input 
Some miRNA 
with multiple 
target sites may 
be omited 
http://diana.imis.athena-
innovation.gr/DianaTools
/index.php 
(Kariakidou et al., 2004) 
 
PITA 
Target site accessibility; 
Free energy 
The secondary 
structure of 3‟UTR is 
considered for miRNA 
interaction 
Low efficiency 
compared to 
other algorithms 
http://genie.weizmann.ac
.il/pubs/mir07/mir07_dyn
_data.html 
(Kertesz et al., 2007)  
UTRs = untranslated regions; PITA = Probability of Interaction by Target Accessibility; DIANA = DNA Intelligent Analysis; AU = adenine/uracil; URL = Uniform 
Resource Locator (website address) 
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The common mRNA target gene lists produced by each program, were filtered using an 
interactive venn diagram tool called Venny v2.0.2 
(http://bioinfogp.cnb.csic.es/tools/venny_old/index.html) (Oliveros, 2007). Common mRNA 
targets were further analyzed using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) to identify Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathways (Fig. 2.9). Thereafter, genes potentially linked to T2D were manually 
selected and confirmed using an online Type 2 diabetes-database (T2D-db), and their 
interacting proteins were determined using a Search Tool for the Retrieval of Interacting 
Genes/Proteins (STRING). In addition, experimentally validated miRNA:mRNA interactions 
were identified for each miRNA using DIANA-TarBase and MiR-TarBase. 
 
Figure 2.9 Schematic representation of microRNA target prediction workflow. 
TargetScan Human DIANA-microT-CDS PITA
MicroRNA target 
prediction analysis
Target genes commonly 
predicted
Venn diagram 
tool
DAVID
KEGG
Type 2 diabetes database
Experimentally validated 
miRNA:mRNA interactions
DIANA-
TarBase 
MiRTarBase
Manually selected genes
Protein-protein 
interactions
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2.9.1 Functional analysis of predicted targets 
The functional role of commonly predicted mRNAs targets for each miRNA was investigated 
using the DAVID gene functional annotation tool, which classifies mRNA targets according to 
biological pathways, functional biological modules, and inter-relationships between groups of 
genes (Huang et al., 2008).  
 
Commonly predicted target gene lists were uploaded, using the official gene symbol 
identifier (gene ID) for each gene. These gene IDs were then converted to gene names 
using the DAVID gene name batch viewer. The genes were functionally annotated to the 
Homo sapien genome. Thereafter, a more comprehensive functional analysis was performed 
by selecting or deselecting functional annotation categories of interest. By selecting the 
functional annotation summary and table, all data including biological processes, metabolic 
function and functional analysis of proteins were retrieved for all genes in the list. All genes 
mapped to the KEGG pathway database were selected. Genes potentially linked to T2D 
were selected based on their regulatory role in metabolic pathways previously associated 
with the development of the disease. Thereafter, the roles of these genes in T2D were 
confirmed using the T2D-db v2.0. The T2D-db is an integrated platform to study the 
molecular basis of T2D (http://t2ddb.ibab.ac.in/home.shtml) which provides information on 
candidate genes, gene expression data, gene/pathway interactions, protein-protein 
interactions and SNP markers and risk factors/complications from a combination of online 
content and published literature previously reported to be associated with T2D (Agrawal et 
al., 2008) (Fig. 2.9).  
 
MiRNA:gene interactions potentially linked to T2D were further investigated using 
experimentally validated miRNA:mRNA target prediction databases such as DIANA-TarBase 
v7.0 (http;//www.microrna.gr/tarbase) and miRTarbase v6.0 
(http://miRTarBase.mbc.nctu.edu.tw/thout). These databases include miRNA:mRNA 
interactions that have been manually curated from information found in thousands of 
previously published studies. For DIANA-TarBase, miRNAs of interest were inserted into the 
search box, and filters including, Homo sapien, normal and high throughput method types, 
all experimental methods and all source types were selected and applied to the search. 
Further details regarding the miRNAs, target genes and interaction information was available 
by selecting the information links. For miRTarbase, standard default settings were used. 
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These databases provides a detailed description of involved genes and miRNAs, a list of 
publications supporting each interaction, the experimental methods used for validation along 
with their outcomes, and links related to KEGG pathways and other external databases (Fig. 
2.9) (Elton and Yalowich, 2015; Hsu et al., 2014). 
2.9.2 Protein-protein interactions 
To identify known and predicted protein-protein interactions of miRNA target gene/proteins, 
STRING v10.0 was used (http://string-db.org/). The interactions include direct (physical) and 
indirect (functional) associations that were derived from three sources including, genomic 
context, high throughput experiments, and previously published literature.  Interactions are 
scored by integrating active predictive mechanisms (neighbourhood, gene fusion, co-
occurrence, co-expression, experiments, databases and text mining of scientific texts), 
resulting in large comprehensive protein networks (Szklarczyk et al., 2014). 
 
On the home page, the name of a predicted miRNA target gene/protein was inserted into the 
search box, and the species Homo sapien was selected to restrict the search. After 
identification of proteins, the protein network was inspected for interactive evidence, and the 
confidence score cut-off was set at 0.95 or greater to filter out false positives. Thereafter, a 
limit was set to show no more than 10 interacting proteins.  
2.9.3 Functional analysis of microRNAs 
To determine the functional role of miRNAs in disease pathogenesis, the Human miRNA 
Disease Database (HMDD) v2.0 was used (http://www.cuilab.cn/hmdd). The HMDD is a 
collection of experimentally supported miRNA-disease associations, which provides data 
from genetics, epigenetics, circulating miRNAs and miRNA-target interactions. This 
database allows users to browse, search and download datasets, as well as submit novel 
data into the database. It is a valuable resource for investigating the roles of miRNAs in 
human disease, and currently contains over 10 000 experimentally supported miRNA-
disease association entries, including 600 miRNA genes and 400 human diseases from 
more than 3000 articles (Li et al., 2014).  
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For each miRNA searched, information about disease association, experimental evidence, 
dysfunction, genetics and epigenetics, presence in circulating biofluids, and the publication 
PubMed reference is given. 
2.9.4 Statistical analysis 
To assess the accuracy of the sequencing data, Chastity scores were calculated using the 
Solexa CHASTITY quality filter. Similar to the Phred quality scoring (Q-scores) system, 
individual bases are assigned a quality score that reflect the probability that the base call is 
correct. This score is quantified by a CHASTITY formula, which excludes clusters with a low 
signal to noise ratio. The default cut-off for filtering is no less than 0.6 in the first 25 bases. 
Statistical significance of differentially expressed miRNAs from the sequencing data was 
determined using the student t-test.  
 
The data selected from the sequencing results were validated using qRT-PCR. Data was 
analysed using Microsoft Excel (2010) and relevant software packages, and statistical 
analysis was performed using GraphPad Prism v5.02. Thereafter, statistical analysis 
between diabetic, pre-diabetic and normo-glycaemic groups were performed using the One-
way analysis of variance (ANOVA), followed by Bonferroni or Tukey post hoc and an 
unpaired t-test where appropriate. All values were presented as the mean ± standard error of 
the mean (SEM), and P values <0.05 were accepted as significant.  
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3. RESULTS 
3.1 Clinical characteristics of participants 
Participants were classified as diabetic (T2D), pre-diabetic or normo-glycaemic (controls) 
according to WHO criteria (World Health Organisation, 2006). Of the 258 study participants, 
12 age-, gender-, ethnicity- and BMI-matched subjects representing diabetics (n=4), pre-
diabetics (n=4) and normo-glycaemics (n=4) were selected for this part of the study.  
 
The clinical parameters of the subjects are shown in Table 3.1. Subjects were matched for 
age and BMI, thus as expected, no significant differences in age (46.8 ± 6.6 vs. 47.3 ± 6.9 
vs. 46.3 ± 5.7 years) and BMI (36.7 ± 3.1 vs. 38.6 ± 3.7 vs. 33.7 ± 1.8 kg/m2) were observed 
between diabetic, pre-diabetic and normo-glycaemic individuals. Blood glucose 
concentrations varied significantly between groups. Fasting plasma glucose concentrations 
were 6.7 ± 0.5 vs. 5.4 ± 0.3 vs. 5.1 ± 0.1 mmol/L for diabetic, pre-diabetic and normo-
glycaemic individuals, respectively (Fig. 3.1A). Two hour glucose concentrations obtained 
from the OGTT were 13.4 ± 0.7 vs. 8.9 ± 0.3 vs. 5.6 ± 0.3 mmol/L (Fig. 3.1B), while the 
percentage of HbA1c was 6.5 ± 0.2 vs. 5.6 ± 0.2 vs. 5.4 ± 0.07 (Fig. 3.1C) for diabetic, pre-
diabetic and normo-glycaemic individuals, respectively. Statistical significance was 
determined using the p-value of ANOVA, followed by Tukey post hoc and an unpaired t-test. 
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Table 3.1 Clinical characteristics of participants. 
N = number of participants; BMI = body mass index; FPG = fasting plasma glucose; OGTT = oral 
glucose tolerance test; HbA1c = glycated haemoglobin A1c; 2 hr refers to a test performed 2 hrs after 
an oral glucose challenge. HDL = high-density lipoprotein; LDL = low-density lipoprotein.  
Blood pressure was measured as systolic/diastolic. 
Boldface values indicate statistical significance. *p≤0.05; p≤0.01;  p≤0.001. 
 
 
 Diabetic Pre-diabetic Normo-glycaemic  
N  4  4  4  
Age (years)  46.8 ± 6.6  47.3 ± 6.9  46.3 ± 5.7  
Gender          Female  Female  Female  
Ethnicity  Mixed ancestry  Mixed ancestry  Mixed ancestry  
BMI (kg/m2)  36.7 ± 3.1  38.6 ± 3.7  33.7 ± 1.8  
Blood pressure (mmHg):  
Systolic- 
Diastolic- 
 
113.7 ± 10.8 
72.3 ± 8.7 
 
131.3 ± 5.9 
83.3 ± 4.4 
 
118.5 ± 4.0 
82.0 ± 3.4  
FPG (mmol/L)  6.7 ± 0.5* 5.4 ± 0.3  5.1 ± 0.1* 
OGTT (2 hr Glucose) 
(mmol/L)  
13.4 ± 0.7   8.9 ± 0.3  5.6 ± 0.3  
HbA1c (%)  6.5 ± 0.2*   5.6 ± 0.2
* 5.4 ± 0.07   
Fasting Insulin (ng/ml)  23.6 ± 6.7  34.8 ± 6.3  21.6 ± 3.1  
2 hr Insulin (ng/ml)  97.8 ± 28.4  264.4 ± 87.7  92.5 ± 23.7  
Fasting C-peptide (ng/ml)  2.7 ± 0.6  2.9 ± 0.4  2.7 ± 0.2  
2 hr C-peptide (ng/ml)  7.9 ± 1.8  11.1 ± 1.7  9.1 ± 0.8  
Glucagon (pg/ml)  91.0 ± 9.5  114.2 ± 16.9  79.6 ± 6.6  
Cholesterol (mmol/L)  5.5 ± 0.7  5.3 ± 0.3  5.4 ± 0.8  
HDL (mmol/L)  1.2 ± 0.1  1.2 ± 0.1  1.3 ± 0.03  
LDL (mmol/L)  3.8 ± 0.6  3.6 ± 0.3  3.6 ± 0.7  
Triglycerides (mmol/L)  1.2 ± 0.3  1.7 ± 0.3  1.1 ± 0.2  
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Figure 3.1 Blood glucose concentrations in diabetic, pre-diabetic and normo-glycaemic individuals. A) 
Fasting plasma glucose, B) 2 hr OGTT glucose, and C) HbA1c levels in diabetics (n=4), pre-diabetics 
(n=4) and normo-glycaemics (n=4). *p<0.05, **p<0.01, ***p<0.001. 
 
Levels of insulin, the primary hormone responsible for maintaining glucose homeostasis, 
was measured in the fasting state, and 30 mins and two hrs after a glucose challenge 
(OGTT). Fasting insulin concentrations were 23.6 ± 6.7 vs. 34.8 ± 6.3 vs. 21.6 ± 3.1 ng/ml 
for diabetic, pre-diabetic and normo-glycaemic individuals, respectively (Fig. 3.2A). After the 
glucose challenge, insulin levels increased in all three groups until 30 mins, whereafter, 
levels decreased in normo-glycaemics, but continued to rise in diabetics and pre-diabetics, 
signifying abnormal glucose metabolism in these groups (Fig. 3.2B). The increase observed 
in pre-diabetics was higher than that observed in diabetics (2.85-fold). 
 
A B
C
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No significant difference was observed when measuring additional parameters, including 
glucagon (91.0 ± 9.5 vs. 114.2 ± 16.9 vs. 79.6 ± 6.6 pg/ml), C-peptide (2.7 ± 0.6 vs. 2.9 ± 0.4 
vs. 2.7 ± 0.2 ng/ml), cholesterol (5.5 ± 0.7 vs. 5.3 ± 0.3 vs. 5.4 ± 0.8 mmol/L), HDL (1.2 ± 0.1 
vs. 1.2 ± 0.1 vs. 1.3 ± 0.03 mmol/L), LDL (3.8 ± 0.6 vs. 3.6 ± 0.3 vs. 3.6 ± 0.7 mmol/L) and 
triglycerides (1.2 ± 0.3 vs. 1.7 ± 0.3 vs. 1.1 ± 0.2 mmol/L), between diabetic, pre-diabetic and 
normo-glycaemic individuals, respectively (Table 3.1).  
Figure 3.2 Fasting and 2hr OGTT insulin concentrations in diabetic, pre-diabetic and normo-
glycaemic individuals. A) Fasting insulin and B) OGTT insulin concentrations in diabetic (n=4), pre-
diabetic (n=4) and normo-glycaemic individuals (n=4) 
.  
A B
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3.2 MicroRNA expression analysis in peripheral blood 
mononuclear cells 
3.2.1 RNA concentration and yield 
Nanodrop spectrophotometry was used to determine the concentration, purity and yield of 
total RNA from PBMCs. The concentration and yield of RNA varied between 31.61 - 124.33 
ng/µl and 1264.40 - 4973.00 ng, respectively (Table 3.2). The A260/A280 and A260/A230 ratios 
are indicative of protein and solvent/salt/other contamination, which varied between 2.03 - 
2.10 and 0.68 - 2.06, respectively, indicating that most of the samples (~83.3 %) contained 
good quality RNA. 
Table 3.2 Total RNA concentration, purity and yield of samples (n=12). 
*RNA concentration was measured at A260 nm 
RNA yield was calculated by multiplying RNA concentration (ng/µl) by the sample volume (40 µl in 
this case) 
 Presence of protein contaminants were measured at A260/A280 nm 
Presence of solvent/salt/other contaminants were measured at A260/A230 nm 
Sample ID Concentration (ng/µl)* Yield (ng) A260/A280 (nm)  A260/A230 (nm)  
1 123.47 4938.60 2.08 2.05 
2 56.45 2258.00 2.08 1.21 
3 119.45 4777.80 2.08 1.94 
4 76.15 3045.80 2.07 2.06 
5 93.16 3726.20 2.09 1.78 
6 124.33 4973.00 2.03 2.02 
7 49.87 1994.80 2.10 1.59 
8 75.85 3034.00 2.08 1.54 
9 100.67 4026.80 2.08 1.87 
10 31.61 1264.40 2.07 0.68 
11 75.69 3027.60 2.08 1.57 
12 108.05 4321.80 2.08 1.06 
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3.2.1.1 RNA quality control  
The success of downstream applications is dependent on the quality and integrity of RNA. 
The quality of the RNA isolated from PBMCs was assessed using the bioanalyser. A gel 
image representing the 12 samples using the RNA Nano Assay and 11 samples using the 
RNA small assay, and an electropherogram representing total and small RNA (miRNA) of 
one of the samples generated by the bioanalyser is indicated in Figure 3.3. The low visibility 
and signal in the miRNA region (Fig. 3.3C-D) may be due to low miRNA content (10%) after 
purification, and could be related to low RNA concentration.  
 
The RNA integrity number (RIN), miRNA as a percentage (%) of total RNA, and the 
concentration (pg/µl) of miRNAs for all 12 samples are presented in Table 3.3. The RIN 
values ranged between 7.30 - 8.50 (7.91 ± 0.12), demonstrating intact and good quality RNA 
for all samples. The percentage and concentration of miRNAs within the samples ranged 
between 7 - 16 % (9.6 ± 0.81) and 230.60 - 897.90 pg/µl (374.9 ± 37.55), respectively.  
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Figure 3.3 A gel image of total RNA and an electropherogram indicating RNA quality. A) Gel image 
representing the 12 RNA samples in lanes 1-12, showing bands representative of intact 28S and 18S 
rRNA molecules. Lane L represents the RNA ladder with the marker for comparative analysis 
indicated in green. B) Electropherogram of total RNA with two main peaks indicating 28S and 18S 
rRNA. C) Gel image representing 11 RNA samples in lanes 1-11, showing the region representative 
of the miRNA length (nt), and an D) electropherogram of small RNA, indicating the region of miRNAs 
between 6 and 40 nt. 
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Table 3.3 Integrity of total RNA, and the percentage and concentration of miRNAs within each sample 
(n=12). 
 
Sample 
 
RIN no. 
 
% miRNA 
 
miRNA concentration (pg/µl) 
1 8.2 11.0 512.9 
2 7.8 9.0 341.6 
3 7.7 7.0 408.7 
4 7.5 9.0 371.0 
5 8.1 10.0 594.2 
6 7.6 16.0 431.1 
7 7.4 8.0 260.8 
8 8.5 7.0 366.0 
9 8.4 7.0 231.9 
10 7.3 11.0 230.6 
11 8.5 7.0 416.8 
12 8.0 13.0 897.9 
RIN = RNA integrity number 
3.2.2 MicroRNA sequencing  
To identify miRNAs that are dysregulated during disease progression, miRNA-enriched total 
RNA from diabetic, pre-diabetic and normo-glycaemic individuals were subjected to next 
generation sequencing on the Illumina HiSeq 2500. All the twelve RNA samples that were 
sent to Arraystar passed their quality control test, which included total RNA quantification and 
quality assurance by NanoDrop ND-1000 spectrophotometry.  Thereafter, a sequencing 
library of the RNA samples were prepared as described in section 2.7, and the quality 
thereof assessed with the Agilent 2100 Bioanalyser. All the samples passed the quality 
control, and were thus subjected to miRNA sequencing. Details of the quality control test 
and the quality assessment of the sequencing library can be found in Appendix 3. 
 
Reads generated by the Illumina HiSeq 2500 instrument were cleaned, adapters trimmed 
and aligned to a known reference human genome in the miRBase v21 database 
(http://www.mirbase.org/), to determine the number of reads generated, as described in 
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section 2.7. The total number of clean reads, adapter trimmed reads, reads aligned to known 
miRNA sequences, and the percentage of reads aligned to the human genome, are 
presented in Table 3.4. 
 
The size distribution of adapter trimmed reads aligned to human reference miRNAs (Table 
3.4, column 3) is illustrated in Figure 3.4. The majority of sequencing read peaks occurred 
around 22 nt as expected. 
 
Table 3.4 The read counts at the different data processing stages. 
Sample 
Name 
Clean 
Reads 
Adapter-trimmed 
Reads (length >= 
15nt) 
Reads aligned to known 
human pre-miRNA in 
miRBase 21 
Percentage of 
aligned reads 
1 6,124,069 6,061,197 5,676,739 93% 
2 3,458,762 3,442,273 3,248,139 94% 
3 5,404,671 5,356,925 5,014,891 94% 
4 4,082,938 4,057,478 3,817,335 94% 
5 4,872,306 4,853,250 4,577,000 94% 
6 3,352,766 3,329,626 3,133,999 94% 
7 4,050,955 4,015,379 3,737,566 93% 
8 5,803,200 5,754,741 5,372,612 93% 
9 7,611,759 7,525,970 6,950,059 92% 
10 6,865,665 6,823,551 6,445,241 94% 
11 6,433,218 6,353,760 5,880,953 93% 
12 5,301,440 5,260,559 4,932,301 93% 
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Figure 3.4 Size distribution of sequencing reads. The size distribution of sequence reads of a 
representative miRNA sample is indicated by total read counts (y-axis) and adapter trimmed read 
length (x-axis).  
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3.2.3 Differential expression of microRNAs during 
Type 2 diabetes progression 
The expression of miRNAs in each sample was determined by comparing the expression of 
each unique sequence to the total number of reads per sample, using equation 2.1 (section 
2.7). A total of 294 miRNAs were found to be expressed among all samples.  Using 
Novoalign, 277, 267 and 267 miRNAs were differentially expressed between diabetics vs. 
normo-glycaemics, pre-diabetics vs. normo-glycaemics, and pre-diabetics vs. diabetics, 
respectively (Table 3.5). A number of novel miRNAs that have not previously been 
annotated in the miRNA database were identified; 35, 33 and 33 novel miRNAs were 
differentially expressed between diabetics vs. normo-glycaemics, pre-diabetics vs. normo-
glycaemics and pre-diabetics vs. diabetics, respectively. Using an arbitrary cut-off of ≥1.1 
expression fold difference and statistical significance set at p≤0.05, five miRNAs (miR-27b, 
miR-98, miR-143, miR-21 and miR-379) were selected for validation by qRT-PCR (Table 
3.6). 
 
MiR-143, miR-21 and miR-379 were upregulated in diabetics compared to pre-diabetics 
(1.75-fold; p≤0.05, 1.22-fold; p<0.01, 1.12-fold; p<0.05, respectively), while miR-27b was 
upregulated in pre-diabetic compared to normo-glycaemic individuals (1.15-fold; p<0.01). In 
contrast, miR-98 was downregulated in diabetics compared to pre-diabetics (1.25-fold; 
p<0.05) and in pre-diabetics compared to normo-glycaemic individuals (1.23-fold; p<0.05) 
(Table 3.6). 
 
Table 3.5 Total number of differentially expressed and novel miRNAs among all samples.  
 
 Diabetic vs. 
Normo-glycaemic 
Pre-diabetic vs. 
Normo-glycaemic 
Pre-diabetic vs. 
Diabetic 
No. of differentially 
expressed miRNAs 
 
277 
 
267 
 
267 
 
Novel miRNAs 
 
35 
 
33 
 
33 
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 Table 3.6 MiRNAs selected for qRT-PCR. 
Positive values indicate miRNAs that were upregulated between groups, while negative values 
indicate miRNAs that were downregulated between groups. D= Diabetics; PD= Pre-diabetics; C= 
Normo-glycaemics. 
 
The hierarchally clustered heat map that was generated to illustrate the differential 
expression of miRNAs between diabetic, pre-diabetic and normo-glycaemic samples is 
shown in Figure 3.5. 
   
Gene symbol Mature miRNA ID Disease group Fold change P-value 
MI0000100 hsa-miR-98 D vs. PD -1.25 0.04 
MI0000459 hsa-miR-143 D vs. PD 1.75 0.05 
MI0000077 hsa-miR-21 D vs. PD 1.22 0.008 
MI0000787 hsa-miR-379 D vs. PD 1.12 0.02 
MI0000440 hsa-miR-27b PD vs. C 1.15 0.003 
MI0000100 hsa-miR-98 PD vs. C -1.23 0.02 
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Figure 3.5 A hierarchal clustered heat map of differentially expressed miRNAs between diabetic, pre-
diabetic and normo-glycaemic individuals. Heat map colours represent relative miRNA expression as 
indicated in the colour key. High and low miRNA expression levels are indicated by red, and green, 
respectively. 
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3.2.4 Quantitative real time PCR validation of 
differentially expressed microRNAs 
Quantitative real time PCR was used to validate the differential expression of miR-27b, miR-
98, miR-143, miR-21 and miR-379, identified by miRNA sequencing. Expression was 
calculated using the ΔΔCt method where RNU6B, miR-454 and miR-425 were used as 
endogenous reference genes, and the average expression in normo-glycaemic individuals 
(n=4) were used as a calibrator. The relative expression of each miRNA was calculated 
using the equation 2.2 in section 2.8.2.1.  
 
Endogenous reference genes were stably expressed in all samples when combined; no 
significant difference was observed between diabetic, pre-diabetic and normo-glycaemic 
groups (Fig. 3.6A), thus making these genes ideal endogenous controls for miRNA 
expression analysis. The expression of miR-143 was upregulated in pre-diabetics compared 
to normo-glycaemic individuals (1.4-fold, p≤0.01) (Fig. 3.6B), while no significant changes 
were observed for miR-21, miR-27b, miR-379 and miR-98 (Fig. 3.6C-F). However, for miR-
27b, a trend towards significance (1.55-fold; p=0.07) was observed between pre-diabetic 
and normo-glycaemic individuals (Fig. 3.6C), confirming sequencing results which showed 
significant upregulation of miR-27b in pre-diabetics compared to normo-glycaemic 
individuals (Table 3.6). 
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Figure 3.6 MiRNA expression analysis using real-time quantitative PCR. A) Average Ct of 
endogenous control, B) relative expression changes of miR-143, C) miR-27b, D) miR-21, E) miR-98, 
and F) miR-379 between diabetic (n=4), pre-diabetic (n=4) and normo-glycaemic individuals (n=4), 
*p<0.05. 
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3.3 MicroRNA expression analysis in serum 
The differentially expressed miRNAs in PBMCs were investigated in serum samples of the 
same individuals. 
3.3.1 Total RNA concentration and yield 
Nanodrop spectrophotometry was used to determine the concentration, purity and yield of 
total RNA-enriched miRNAs from serum samples. The concentration and yield of total RNA 
varied between 11.15 - 19.05 ng/µl and 227.10 - 380.90 ng, respectively (Table 3.7), 
indicating lower total RNA amounts in serum compared to PBMCs, as expected. The 
A260/A280 and A260/A230 ratios varied between 1.26 - 1.49 nm and 0.29 - 0.44 nm, respectively. 
These low ratios may be indicative of possible protein-bound miRNA detection or cellular 
contamination from miRNA origin. 
 
Table 3.7 Total RNA concentration, purity and yield of serum samples (n=12). 
Sample ID Concentration (ng/µl)* Yield (ng) A260/A280 (nm)  A260/A230 (nm)  
1 17.03 340.60 1.49 0.29 
2 17.16 343.20 1.34 0.27 
3 14.51 290.10 1.30 0.28 
4 12.11 242.10 1.33 0.28 
5 13.70 273.90 1.27 0.31 
6 19.05 380.90 1.26 0.41 
7 12.78 255.50 1.29 0.44 
8 17.96 359.20 1.44 0.21 
9 14.80 296.00 1.39 0.21 
10 14.03 280.50 1.28 0.42 
11 11.58 231.60 1.31 0.17 
12 11.36 227.10 1.42 0.07 
*RNA concentration was measured at A260 nm 
RNA yield was calculated using total RNA concentration (ng/µl) in 14 µl of total sample volume 
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Presence of protein contaminants were measured at A260/A280 nm 
Presence of solvent/salt/other contaminants were measured at A260/A230 nm 
 
3.3.2 MicroRNA quality control  
The quality of the RNA-enriched miRNAs isolated from serum samples was assessed using 
the small Agilent bioanalyser for total miRNA detection. The percentage and concentration of 
miRNAs within the 12 samples ranged between 50 - 89 % (67.4 ± 9.4) and 134.40 – 1017.70 
pg/µl (336.0 ± 249.7), respectively, and is presented in Table 3.8. 
 
 Table 3.8 Percentage and concentration of miRNAs in each serum sample (n=12). 
 
 
Sample % of miRNA miRNA concentration (pg/µl) 
1 74 330.10 
2 71 318.40 
3 69 134.40 
4 89 260.70 
5 67 161.00 
6 69 331.50 
7 65 191.80 
8 50 117.50 
9 69 1017.70 
10 57 179.90 
11 66 509.50 
12 63 479.90 
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 3 RESULTS 
75 
 
3.3.3 Differential expression of microRNAs in serum 
The expression of miR-27b, miR-98, miR-143, miR-21 and miR-379 in serum of diabetic 
(n=4), pre-diabetic (n=4) and normo-glycaemic individuals (n=4) was calculated using the 
ΔΔCt methods and using miR-425 as the endogeneous control (Fig. 3.7).  
 
Of the three endogenous controls investigated, Normfinder showed that miR-425 was the 
most stably expressed among all samples, with no significant difference between diabetic, 
pre-diabetic and normo-glycaemic groups (Fig. 3.7A). In addition, the exogenous synthetic 
spike in control (miR-39); used to control for technical variation, was stably expressed in all 
samples (Fig. 3.7B), suggesting efficiency of RNA extraction, cDNA synthesis and PCR 
amplification. 
 
MiR-27b was upregulated (2.0-fold; p≤0.05) in pre-diabetic compared to normo-glycaemic 
individuals (Fig. 3.7C). Although miR-21, miR-379, miR-98 and miR-143 were also detected 
in serum, none of them were differentially expressed between the groups (Fig. 3.7D-G). 
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Figure 3.7 Expression of miRNAs in the serum of diabetic, pre-diabetic and normo-glycaemic 
individuals, using real-time quantitative PCR. A) Average Ct of endogenous control, B) average Ct of 
exogenous control, relative expression changes of C) miR-27b,  D) miR-143, E) miR-21, F) miR-98 
and G) miR-379 between diabetic (n=4), pre-diabetic (n=4) and normo-glycaemic individuals (n=4), 
*p<0.05.  
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3.4 Novel microRNAs  
A total of 151 potential novel miRNA precursors (both 3p and 5p) were identified by next 
generation miRNA sequencing. MiRDeep algorithms showed that only 130 novel miRNA 
precursor structures were predicted to be significant across the genome. Of these, 33, 35 
and 33 novel miRNAs were shown to be differentially expressed in pre-diabetic compared to 
normo-glycaemic individuals, diabetic compared to normo-glycaemic individuals, and pre-
diabetics compared to diabetics, respectively. Comparative analysis of the differentially 
expressed miRNAs in each of the groups identified 23 novel miRNAs that were commonly 
differentially expressed in all 3 groups (pre-diabetic vs. normo-glycaemic, diabetic vs. normo-
glycaemic and pre-diabetic vs. diabetic) (Fig. 3.8). Six miRNAs were differentially expressed 
in both diabetic and pre-diabetics compared to normo-glycaemic individuals, six miRNAs 
were differentially expressed in diabetics compared to both pre-diabetic and normo-
glycaemic individuals, and four miRNAs were differentially expressed in pre-diabetics 
compared to diabetics and normo-glycaemic individuals (Fig. 3.8).  
Figure 3.8 Venn diagram showing novel miRNAs commonly expressed between diabetic, pre-diabetic 
and normo-glycaemic groups.  
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3.4.1 Quantitative real time PCR validation of novel 
microRNAs 
Five novel miRNAs (MYNO22, MYNO59, MYNO66, MYNO8, MYNO95) were selected for 
validation using qRT-PCR. Validation was performed in the same RNA samples used for 
miRNA sequencing; diabetic (n=3), pre-diabetic (n=4) and normo-glycaemic (n=4) samples. 
One diabetic sample did not have sufficient RNA for analysis. Quantitative real-time PCR 
confirmed the expression of MYNO22, MYNO59, MYNO66, MYNO8, MYNO95 in all 
samples (Fig. 3.9). 
 
The relative expression levels of these miRNAs was calculated using the average Ct of 
RNU6B, miR-454 and miR-425 as endogenous reference genes for normalization (Fig. 
3.9A). MYNO59, MYNO95 and MYNO66 was downregulated in diabetics compared to 
normo-glycaemic individuals (-0.4-fold; p≤0.05, -0.5-fold; p≤0.05, -0.5-fold; p≤0.01) (Fig. 
3.9B-D). In addition, MYNO66 and MYNO8 was downregulated in pre-diabetics compared to 
normo-glycaemic individuals (-0.5-fold; p≤0.05), and in diabetics compared to pre-diabetics 
(-0.8-fold; p≤0.05), respectively (Fig. 3.9D-E). No significant differential expression was 
observed for MYNO22 (Fig. 3.9F).  
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Figure 3.9 Validation of novel miRNAs using quantitative real-time PCR. A) Average Ct of 
endogenous control, relative expression changes of B) MYNO59, C) MYNO95, D) MYNO66, E) 
MYNO8, and F) MYNO22 between diabetic (n=3), pre-diabetic (n=4) and normo-glycaemic individuals 
(n=4), *p<0.05, **p<0.01. 
A
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3.5 Bioinformatics 
3.5.1 Messenger RNA target prediction analysis 
Messenger RNA (mRNA) target prediction for each of the five selected differentially 
expressed miRNAs (section 3.2.3) was conducted using three target prediction programs 
(TargetScan, DIANA and PITA) that differ in the algorithms they use for prediction (Table 
3.9). The number of mRNA targets predicted for miRNAs varied according to the target 
prediction program used. For example, for miR-27b, TargetScan, DIANA and PITA predicted 
71, 2107 and 1553 mRNA targets, respectively. Of these 39% of targets predicted by 
TargetScan were commonly predicted by all three programs, while 1.3% and 1.8% of targets 
predicted by DIANA and PITA, respectively, were commonly predicted by all three programs. 
TargetScan had the highest percentage of true predicted targets compared to DIANA and 
PITA, based on the assumption that mRNA targets predicted by all three programs are „true‟ 
targets. 
 Table 3.9 Number of commonly predicted targets between TargetScan, DIANA and PITA. 
TargetScan predicts targets based on seed match complementarity and sequence conservation. 
DIANA predicts targets based on free energy binding and complementarity. 
PITA predicts targets based on target site accessibility and free energy. 
*Commonly predicted targets determined using the venny tool (Oliveros 2007) 
Percentages (%) were determined by dividing the commonly predicted targets by the total number of 
targets predicted by the program, and multiplying by 100. 
 
Number of targets predicted 
Mature miRNA TargetScan DIANA  PITA  Common* 
miR-27b 71 (39%) 2107 (1.3%) 1553 (1.8%) 28 
miR-379 38 (18%) 377 (1.8%) 665 (1.5%) 7 
miR-21 164 (7.9%) 554 (2.3%) 975 (1.3%) 13 
miR-98 46 (26%) 991 (1.2%) 1291 (0.9%) 12 
miR-143 279 (26.1%) 1062 (6.8%) 289 (25%) 73 
 
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 3 RESULTS 
81 
 
3.5.2 Functional analysis of predicted targets 
Pathway analysis of the commonly predicted mRNA target genes was conducted using the 
DAVID functional annotation tool. Commonly predicted mRNA target gene lists for the five 
miRNAs (Table 3.9) were copied into DAVID for pathway analysis. Results of the individual 
miRNAs and their predicted mRNA targets are indicated in Table 3.10. A total of 40 
predicted mRNA target genes were mapped to KEGG pathways (Table 3.10, column 3). Of 
these, 13 predicted target genes were selected based on their potential role in T2D disease 
progression, as described in section 2.9.1 (Table 3.10, column 4). Thereafter, the role of 
these targets in T2D was confirmed using the T2D-db. Three of the 13 predicted target 
genes (peroxisome proliferator-activated receptor gamma (Ppagr), the insulin receptor (Insr) 
and v-Ki-ras2 kirsten rat sarcoma viral oncogene homolog (Kras) were identified in this 
database.  
 
For miR-27b, 12 of the 28 mRNA targets commonly predicted by TargetScan, DIANA and 
PITA mapped to KEGG pathways. Of these, two genes; peroxisome proliferator-activated 
receptor gamma (Pparg) and vascular endothelial growth factor C (Vegf-c), which plays a 
role in the PPARG and mTOR signaling pathways, respectively, were selected as genes 
linked to T2D.  
 
For miR-379, two of the seven mRNA targets commonly predicted by TargetScan, DIANA 
and PITA mapped to KEGG pathways. Of these, the insulin receptor (Insr) gene which plays 
a role in the development of T2D through its effect on the insulin signaling pathway was 
selected. 
 
Four of the 13 mRNA target genes commonly predicted by TargetScan, DIANA and PITA for 
miR-21 mapped to KEGG pathways. Of these, one target gene; tuberous sclerosis 1 (Tsc1), 
was selected due to its role in T2D through effects on the mTOR and insulin signaling 
pathway.  
 
For miR-98, four of the 12 mRNA target genes commonly predicted by TargetScan, DIANA 
and PITA mapped to KEGG pathways. Of these, three target genes; mitogen-activated 
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protein kinase 3 (Map4k3), Unc-51-like kinase (Ulk2) and stearoyl-CoA desaturase (delta-9-
desaturase) (Scd) were potentially linked to T2D, and is predicted to play a role in MAPK, 
mTOR and PPARG signaling pathways, respectively. Additionally, Scd may also play a 
potential role in the biosynthesis of unsaturated fatty acids.  
 
For miR-143, 18 of the 73 mRNA targets commonly predicted by TargetScan, DIANA and 
PITA mapped to KEGG pathways. Of these, six target genes; fibroblast growth factor 1 
(Fgf1), calcium channel voltage-dependent alpha 1A subunit (Cacna1a), protein kinase C, 
epsilon (Prkce), tao kinase 2 (Taok2), v-ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
(Kras), and an independent companion of mTOR complex 2 (Rictor) may play a role in T2D 
disease progression. These genes are predicted to be involved in mTOR, MAPK, insulin and 
chemokine signaling.  
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Table 3.10 Significantly differentially expressed miRNAs and their mRNA targets. Genes listed were 
identified to play a potential role in T2D-related metabolic pathways, identified using the 
DAVID/KEGG pathway database. 
*Manually selected genes that have previously been reported to play a role in metabolic pathways 
linked to T2D.  
MiRNA 
No. of 
predicted 
mRNA targets 
No. of  linked 
to KEGG 
pathway 
Genes linked 
to T2D* 
Role of genes in T2D 
related metabolic 
pathways 
miR-27b 28 12 
Pparg PPARG signaling 
Vegf-c mTOR signaling 
miR-379 7 2 Insr 
Insulin signaling and T2D 
disease pathogenesis 
miR-21 13 4 Tsc1 
mTOR and insulin 
signaling 
miR-98 12 4 
Map4k3 MAPK signaling 
Ulk2 mTOR signaling 
Scd 
PPARG signaling and 
the biosynthesis of fatty 
acids 
miR-143 73 18 
Rictor mTOR signaling 
Taok2 MAPK signaling 
Cacna1a 
T2D disease 
pathogenesis 
Fgf1 MAPK signaling 
Prkce 
T2D disease 
pathogenesis 
Kras 
MAPK, chemokine and 
insulin signaling 
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3.5.3 Protein-protein interactions regulated by 
differentially expressed microRNAs 
Protein-protein interactions possibly regulated by the differentially expressed miRNAs were 
investigated using the protein interaction database called STRING. Predicted mRNA target 
gene/proteins were investigated, and related interacting proteins are illustrated in Appendix 
4. For example, miRNA-27b target: vascular endothelial growth factor C (VEGFC) interacts 
with fms-related tyrosine kinase 4 (FLT4), kinase insert domain receptor (KDR), neuropilin 2 
(NRP2), fms-related tyrosine kinase 1 (FLT1), and insulin-like growth factor 1 receptor 
(IGF1R). The estimated likelihood that the predicted proteins interact in the same metabolic 
map in the KEGG database was indicated by a 95% confidence score generated by the 
active prediction methods in the STRING tool.  
3.5.4 Functional analysis of microRNAs 
In addition to functional analysis of mRNA target genes, biological activity of the differentially 
expressed miRNAs was also explored. Using HMDD, the biofluid and disease association of 
the differentially expressed miRNAs were investigated using the miRNA database, HMDD. 
MiR-27b, miR-143 and miR-21 were previously identified in biofluids such as serum, plasma, 
urine and faeces, and were mostly found to be associated with neoplasms and different 
types of cancers (Table 3.11). Circulating miR-21 have also been found to be associated 
with T2D (Table 3.11). In contrast, miR-98 and miR-379 has not yet been detected in its 
circulatory form. 
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Table 3.11 Functional analysis of miRNAs using the HMDD (Li et al., 2014). 
MiRNA ID Bio-fluid detection Disease association 
hsa-miR-27b urine urinary bladder neoplasms 
miR-379 none n/a 
miR-21 plasma and serum fatty liver non-alcoholic disease, neoplasm, 
hepatitis C, different cancer types, and T2D 
miR-98 none n/a 
miR-143 faeces pancreatic neoplasms 
3.5.5 Experimental validation of microRNA:mRNA 
target interactions 
The databases DIANA-TarBase and miRTarBase were used to investigate whether the 
interactions between differentially expressed miRNAs (miR-27b and miR-143) and their 
predicted mRNA targets were experimentally validated. MiRNA:mRNA interactions were 
validated using a range of experimental methods including Reporter assays, Western blot, 
qRT-PCR, Microarrays and others (Table 3.8). The predictive scores ranged from 0 - 1, with 
1 representing the highest likelihood of an interaction, and 0 representing the lowest 
likelihood of a true interaction (Table 3.8). Both DIANA-TarBase and miRTarBase gave high 
predictive scores for the interaction between miR-27b and PPARG, and between MiR-143 
and KRAS. 
   
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 3 RESULTS 
86 
 
Table 3.12 Experimental validation of miRNA:mRNA target interactions.  
  Prediction 
program 
Validation method   
 
 
miRNA  
 
 
Target 
gene 
 
 
DIANA-
Tarbase 
 
 
miRTar
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Predictive 
score 
 
 
Refer
ences 
miR-27b Pparg yes yes      1 3 
miR-143 Kras yes yes      0.994 5 
  
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 4 DISCUSSION 
87 
 
4. DISCUSSION 
The prevalence of T2D continues to increase worldwide, placing a huge financial and health 
burden on governments, particularly those in middle and low income countries (Whiting et 
al., 2011). The costs to treat T2D are worsened by the multitude of associated morbidities 
such as CVD, stroke and peripheral vascular disease (Fowler, 2008). Without effective 
intervention, the WHO predicts that T2D may become the world‟s greatest health challenge 
within the next 25 years, a prediction supported by the high numbers of undiagnosed cases 
globally, and the alarming increase of T2D in children (WHO, 2006). 
 
A major priority in T2D research is the prevention, improved diagnosis and management of 
the disease. It is widely believed that the identification of individuals during the pre-diabetic, 
sub-clinical stage of disease will facilitate intervention strategies which may prevent or delay 
their disease progression (Sherwin et al., 2004). Such intervention strategies could include 
lifestyle modifications such as diet and exercise, or therapeutic interventions that could 
protect against insulin resistance, β-cell dysfunction and obesity. The early identification of 
individuals who are at risk of T2D, before the clinical onset of symptoms, will decrease the 
burden of T2D and its micro- and macro-vascular complications.  
 
Research efforts to reduce the burden of T2D by early intervention are underpinned by the 
need for biomarkers to identify subclinical disease. Despite the availability of the OGTT, FPG 
and HbA1c, limitations of these screening and diagnostic tests prevent the identification of 
high risk individuals or the early identification of T2D before the manifestation of micro- and 
macro-vascular complications. Recently a number of studies have reported that miRNAs 
play an important role in various diseases, including T2D (Guay et al., 2011). Although 
miRNAs were first identified in tissue and play important regulator roles in cells, they also 
occur in PBMCs, or as free circulating miRNAs in serum and plasma, suggesting that they 
could be used as potential, minimally invasive blood-based biomarkers of disease (Lagos-
Quintana et al., 2002; Mao et al., 2013). The ultimate goal would be to develop a reliable, 
affordable, straightforward point-of-care device that can analyze a patient‟s serum/plasma, 
urine or saliva in a clinical setting, allowing on-site miRNA detection and disease diagnosis. 
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In this study we hypothesized that circulating miRNAs differ during disease progression, and 
that these epigenetic marks could be used as biomarkers which will differentiate between 
normo-glycaemic, pre-diabetic and diabetic (T2D) individuals.  
 
4.1 Clinical characterization of participants 
Study participants were classified as diabetic, pre-diabetic or normo-glycaemic according to 
their FPG, OGTT and HbA1c levels. Higher fasting insulin and 2 hr OGTT insulin 
concentrations were observed in pre-diabetic compared to normo-glycaemic individuals, 
consistent with studies that have reported that pre-diabetes is characterized by insulin 
resistance and hyperinsulinaemia (Beagley et al., 2014). During insulin resistance, insulin 
sensitive cells fail to respond to physiological concentrations of insulin, causing β-cells to 
compensate by increasing insulin secretion, resulting in hyperinsulinaemia and 
hyperglycaemia, as observed in the pre-diabetic individuals in this study. Similarly, fasting 
and 2 hr C-peptide concentrations were higher in pre-diabetic compared to diabetic and 
normo-glycaemic individuals. C-peptide is the cleavage product produced during the 
processing of insulin from the proinsulin molecule to mature insulin, and is secreted by β-
cells in equimolar concentrations to insulin (Akuri, 2014). It is widely believed that 
quantification of C-peptides are better markers of β-cell secretory activity, since they are 
more stable in blood over longer time periods compared to insulin (~6-fold greater half-life) 
(Palmer et al., 2004). Insulin concentrations in diabetics were decreased compared to 
normo-glycaemic individuals, illustrating possible β-cell dysfunction and failure to secrete 
insulin (Kahn, 2003).  
 
Both insulin and glucagon concentrations were increased in pre-diabetics and diabetics 
compared to normo-glycaemic individuals, consistent with the hypothesis that dysglycaemia 
causes dysregulation of regulatory mechanisms in pancreatic cells, such as the failure to 
inhibit glucagon secretion from alpha (α) cells during hyperglycaemia (Moon and Won, 
2015). The glucagon-like peptide hormone (GLP-1) is an incretin hormone secreted by the 
ileum in response to nutrients. Activation of GLP-1 stimulates insulin secretion and inhibits 
glucagon secretion in a glucose-dependent manner under normal fed conditions. During 
T2D, defects in α-cells cause impaired glucose sensing, thus preventing glucagon inhibition 
(Dunning et al., 2005). It has also been reported that α-cells become resistant to insulin 
under conditions of impaired glucose sensing. For example, α-cell specific insulin receptor 
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knockout mice, exhibited mild glucose intolerance, hyperglycaemia and hyperglucagonaemia 
compared to control mice in the fed state, suggesting dysregulation of insulin and glucose 
sensing mechanisms (Kawamori et al., 2009). 
 
Despite differences observed in insulin, C-peptide and glucagon concentrations, these were 
not statistically significant. The failure to attain statistical significance could be due to the 
small sample size and heterogeneity between the individuals studied. Individuals of mixed 
ancestry originate from a combination of different ethnic backgrounds including Khoisan, 
African, Caucasian and Asian, thus represent a diverse genetic group (de Wit et al., 2010). A 
number of studies have reported the complexities of studying mixed ancestry individuals. 
However we selected this population group due to their high prevalence in the Western 
Cape of South Africa where the study was based, and because of the prevalence of T2D 
within mixed ancestry communities (Erasmus et al., 2012). Erasmus et al. (2012) reported 
that the prevalence of T2D was 28.2% in a mixed ancestry cohort in Bellville South, a suburb 
in the Western Cape. A previous study conducted by Levitt and colleagues in a mixed 
ancestry community in Mamre, another suburb in the Western Cape, reported a prevalence 
of 10.8% (Levitt et al., 1993). The same authors (Levitt et al., 1993) reported that the 
prevalence of T2D was 8.0% amongst black Africans living in African residential areas in 
Cape Town. These findings support the selection of mixed ancestry individuals to investigate 
the association between miRNAs and T2D progression. 
 
Diabetes is often characterized by hyperlipidaemia (Krauss, 2004). In this study, no 
difference in the lipid profile (HDL, LDL, cholesterol and triglycerides) between diabetic, pre-
diabetic and normo-glycaemic individuals was observed. Study participants in each group 
were matched according to BMI, to reduce confounding factors due to bodyweight, and 
could explain the failure to observe differences in the lipid profile between these groups. 
Several studies have shown the association between lipid composition and BMI (Shamai et 
al., 2011; Szczygielska et al., 2002). Szczygielska et al. (2002) reported that triglyceride and 
total cholesterol concentrations were higher in obese individuals compared to normal weight 
subjects (BMI<25 kg/m2), while lower HDL cholesterol concentrations were observed in 
obese individuals compared to normal subjects. Another study showed a positive 
relationship between BMI and triglycerides in individuals with a wide range of BMI values 
(Shamai et al. 2011). All participants in this study were either overweight (BMI>25 kg/m2) or 
obese (BMI>30 kg/m2) with a mean BMI greater than 33 kg/m2.  
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A number of factors including ethnicity, age, gender, BMI, socioeconomic status, nutrition, 
toxins, physical inactivity, alcohol, smoking, etc. are known to modify the epigenome and 
cause epigenetic dysregulation (Hamilton, 2011). Unfortunately, many of these factors, such 
as alcohol consumption, smoking, physical activity and diet were not known for the 
participants of this study. Participants were recruited from communities with similar socio-
economic statuses, so as to minimize the effects of environmental influences. Moreover, 
individuals were matched for ethnicity, age, gender and BMI to further minimize confounding 
and bias. 
4.2 MicroRNA sequencing 
Next generation sequencing has gained popularity for assessing RNA abundance in 
biological samples, and as a high throughput platform for detecting differentially expressed 
known and novel miRNA expression profiles (David, 2013; Tam et al., 2014). The majority of 
sequencing reads obtained with NGS varied between 19 nt and 24 nt in length, correlating 
with the average size of miRNAs in the human genome (Felekkis et al., 2010). An average of 
4.9 million reads were mapped to small RNA species, with a total of 294 miRNAs expressed 
among the 12 samples. Illumina technology can detect between 3.4 million and 3 billion 
reads per run (Moldoval et al. 2014). Total read counts vary according to sample size, 
sample type and disease association (Lopez et al., 2015). 
 
Our study identified 277, 267 and 267 differentially expressed miRNAs between diabetics vs. 
normo-glycaemics, pre-diabetics vs. normo-glycaemics, and pre-diabetics vs. diabetics, 
respectively. The presence of such a large population of differentially expressed miRNAs 
between diabetic, pre-diabetic and normo-glycaemic individuals provide support for their 
involvement in the regulation of genes important in the development of T2D (Karolina et al., 
2011). For example, a study conducted in HEK293T cells using the Dual-Luciferase assay 
reported that high expression levels of miR-199 as seen in T2D, represses GLUT4 
expression (Yan et al., 2014). Overexpression of miR-199 reduces glucose uptake in rat L6 
muscle cells, as repression of GLUT4 inhibits insulin-stimulated glucose uptake (Yan et al., 
2014). Karolina et al. (2011) showed significant upregulation of miR-144 in PBMCs of T2D 
patients compared to healthy controls. Furthermore, a significant downregulation of IRS1 
was observed when miR-144 was overexpressed, and a significant upregulation was 
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observed when miR-144 was inhibited, thus, illustrating the potential role of miR-144 in the 
insulin signaling pathway (Karolina et al., 2011).  
 
Although NGS provides a high throughput platform that is highly sensitive and specific for 
miRNA detection (Motameny et al., 2010), the high cost of the technique limits the amount of 
samples that can be investigated. Due to inter-individual heterogeneity, as observed in our 
study, large sample sizes are required to attain statistical and clinical significance.   
4.3 Validation of microRNA sequencing by quantitative 
real time PCR 
The differential expression of five miRNAs identified by NGS was validated by qRT-PCR in 
the same PBMC samples that were previously used. Using the arbitrary cut-off threshold 
values set by ArrayStar; five differentially expressed miRNAs (miR-143, miR-98, miR-21, 
miR-27b and miR-397) were selected for further analysis. Of the five miRNAs tested, qRT-
PCR results for miR-27b confirmed sequencing results, showing a trend towards significance 
in pre-diabetics compared to normo-glycaemic individuals. None of the expression 
differences of the other four miRNAs identified by NGS were confirmed by qRT-PCR. 
However, miR-143 was significantly upregulated in pre-diabetics compared to normo-
glycaemics in contrast to sequencing, where a significant downregulation was observed in 
pre-diabetics compared to diabetics. No expression differences for the other three miRNAs 
were observed between disease groups.  
 
The discrepancies between qRT-PCR and sequencing results could be due to technical 
differences of the techniques. For qRT-PCR, technical aspects that could influence the 
results include template quality, poor assay efficiency, primer–dimers (Klein, 2002), 
subjectivity in data analysis, and the selection of reference genes (Bustin and Nolan, 2004). 
Quantitative real time PCR produces expression data relative to stably expressed reference 
genes, whereas miRNA sequencing data generates millions of reads per sample, providing a 
more absolute representation of miRNA expression. This enables the highly sensitive 
sequencing technique to detect both high and low miRNA expression levels mapped to the 
entire human reference genome. Although qRT-PCR provides an easy, rapid and cost 
effective platform for quantifying miRNA expression profiles, NGS is considered more 
sensitive than qRT-PCR, and can detect novel miRNAs (Motameny et al., 2010). 
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Furthermore, a lack of consensus exists regarding the selection of reference genes used for 
normalizing miRNA expression profiles in qRT-PCR (Marabita et al., 2015). The most 
common choice of reference genes are endogenous miRNAs that are stably expressed 
among all samples. However, the selection of these genes may be arbitrary in a small 
sample size when based entirely on the variability of raw data, without further computational 
analysis. In our study NormFinder was used to confirm the appropriate selection of reference 
genes for normalisation, while some other studies use BestKeeper or eNorm, to identify the 
most suitable reference genes (Liu et al., 2014). A number of published articles select 
reference genes randomly without validation, which could explain the lack of comparability in 
miRNA expression patterns in these studies (Tiberio et al., 2015). Thus, although qRT-PCR 
is routinely used to validate NGS data, it has a number of limitations, which should be taken 
into account during data analysis. 
4.4 Functional analysis of predicted messenger RNA 
targets 
To gain insight into the biological function of these miRNAs, mRNA targets were predicted 
using three target prediction software programmes; TargetScan, PITA and DIANA. These 
programs differ in the algorithms they use for target prediction. TargetScan predicts mRNA 
targets based on sequence complementarity and conservation (Friedman et al., 2009; Lewis 
et al., 2005), DIANA focuses on the minimum binding energy between miRNA and 
sequences in the mRNA target region (Kiriakidou et al., 2004; Maragkakis et al., 2009), and 
PITA focuses on free energy and target site accessibility (Witkos et al., 2011). Since target 
prediction programs are prone to predicting false-positives (Kertesz et al., 2007; Kiriakidou et 
al., 2004; Lewis et al., 2005), only targets that were commonly predicted by all three 
programs were selected, thereby reducing the chance of identifying false-positive targets. In 
our study, TargetScan had a higher likelihood of predicting a true mRNA target compared to 
DIANA and PITA, based on the assumption that the commonly predicted targets were true-
positives. In recently published literature, TargetScan has been considered one of the best 
target prediction programs, as it incorporates evolutionary conservation i.e. miRNA and 
mRNA sequences highly conserved across a wide range of species, as well as strict 
complementarity between sequences (Lewis et al., 2005). Algorithms which consider 
complementarity along with conserved nature and/or free energy have been shown to 
perform better than methods that consider a single characteristic only (Yue et al., 2009).  
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The functional role of mRNA targets were investigated using the DAVID gene functional 
annotation tool, which classifies mRNA targets according to their inter-relationships between 
gene groups and biological terms, specific biological pathways, and functional significance in 
biological modules (Huang et al., 2007). A common problem encountered with DAVID is that 
the output of data is often large and overwhelming (Huang et al., 2007; Huang et al., 2008). 
Therefore, we focused our analysis on mRNA targets that mapped to KEGG pathways. 
Messenger RNA genes that were associated with metabolic pathways linked to the 
development of T2D were selected based on personal knowledge.  
 
The personal selection of genes linked to T2D may have missed important genes due to the 
limitations inherent in personal knowledge. The selected T2D-related genes were confirmed 
using the T2D-db. The T2D-db provides information of all molecular factors known to be 
involved in the pathogenesis of T2D in humans (Agrawal et al., 2008). Three of the selected 
genes (Pparg, Kras and Insr) known to be involved in T2D disease development were 
associated with the database. The lack of association between other genes may be due to 
missing information of newly discovered T2D-related genes, since the database was last 
updated in 2009. 
 
To identify signaling cascades that may be affected by miRNA regulation, interacting 
proteins of predicted miRNA target gene/proteins were evaluated and identified using 
STRING. Analyzing gene targets in the context of protein regulation provides insight into 
how the dynamic biological system is controlled (Szklarczyk et al., 2014). The interactions 
between proteins identified in our study illustrates various metabolic pathways implicated in 
the pathogenesis of T2D, suggesting that miRNA dysregulation forms part of a wider 
network of complex regulatory systems (Liang and Li, 2007). 
4.5 Functional analysis of microRNAs 
In addition to conducting functional analysis of target genes, we also investigated the 
biological role of miRNAs in circulation using HMDD. This database provides information 
about the association of miRNAs with disease.  For example, miR-27b was previously 
investigated in a study using miRNAs as urinary biomarkers in cancer patients (Miah et al., 
2012). MiR-143 was expressed at high levels in faecal samples of pancreatic cancer patients 
and healthy individuals (Link et al., 2012). Interestingly, miR-21 was decreased in plasma of 
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T2D patients compared to normo-glycaemic individuals (Zampetaki et al., 2010). MiR-98, 
and miR-379 have not yet been discovered in its circulatory form. 
4.6 Computational validation of microRNA:mRNA 
target interactions 
In this study, we investigated the relationship between differentially expressed miRNAs and 
their T2D-related target genes, using DIANA-TarBase and miRTarBase, with a special focus 
on miR-27b and miR-143, as these showed significance in the validation analysis. These 
databases provide information for miRNA:mRNA target interactions that have previously 
been experimentally validated, providing a list of publications for each interaction (Elton and 
Yalowich, 2015; Hsu et al., 2014). The analysis showed high predictive scores for previously 
experimentally validated miRNA:mRNA target interactions between miR-27b and Pparg, and 
between miR-143 and Kras, by three or more techniques. For example miR-27b:Pparg 
interaction was validated using a Luciferase reporter assay, Western blot and qRT-PCR 
(Karbiener et al., 2009; Jennewein et al., 2010; Lee et al., 2012), while miR-143:Kras was 
validated using a Luciferase reporter assay, Western blot, qRT-PCR and Microarrays (Chen 
et al., 2009; Lin et al., 2009; Pagliuca et al., 2012; Ni et al., 2012), illustrating direct binding 
of miRNAs on predicted target sites. 
4.7 Novel microRNA 
Since their initial discovery in C. elegans in 1993 (Lee et al., 1993), over 30,000 mature 
miRNA sequences have been identified in more than 150 species (miRBase v21). 
Conservative estimates indicate that over 1000 miRNAs are found in the human genome, 
where they regulate a large number of genes (Ardekani and Naeini, 2010). Our sequencing 
data identified a total of 151 novel miRNAs among all samples. Of these, 35, 33 and 33 
novel miRNAs were differentially expressed in diabetic vs. normo-glycaemic, pre-diabetic vs. 
normo-glycaemic and pre-diabetic vs. diabetics, respectively. Validation of novel miRNAs 
identified by sequencing is required before they can be regarded as a „true‟ finding (Juan et 
al., 2014). In this study, the expression of five novel miRNAs (MYNO22, MYNO59, MYNO66, 
MYNO8 and MYNO95) was confirmed using qRT-PCR. The sequences of these novel 
miRNAs will be submitted into the online miRNA registry for the assignment of an 
appropriate miRNA gene name, after a manuscript describing experimental validation has 
been accepted (Griffiths-Jones et al., 2006). 
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Both sequencing and qRT-PCR showed that three of the five novel miRNAs, MYNO59, 
MYNO95 and MYNO66 were downregulated in diabetics compared to normo-glycaemic 
individuals. Moreover, MYNO66 was significantly downregulated with disease progression, 
i.e. decreased expression in normo-glycaemics > pre-diabetics > diabetics. These results 
suggest that these novel miRNAs, particularly MYNO66, are associated with disease 
development, warranting further investigation of their role in T2D. Investigating the 
expression of these miRNAs under different metabolic conditions, and then identifying their 
mRNA targets, may provide a better understanding of their role in the development of T2D. 
4.8 MicroRNA profiling in serum 
Circulating miRNAs that occur cell-free in plasma and serum have attracted considerable 
interest as biomarkers for numerous diseases due to their highly stable nature (Chen et al., 
2008). The expression of miRNAs that were shown to be differentially expressed in PBMCs 
was investigated in serum samples of the same individuals. All five miRNAs were detected in 
serum of diabetic, pre-diabetic and normo-glycaemic individuals. Of these, only miR-27b was 
significantly upregulated in pre-diabetics compared to normo-glycaemic individuals. These 
results were consistent with results observed for sequencing and qRT-PCR in PBMCs. No 
difference in the expression of the other four miRNAs was observed.  
 
The discrepancies of miRNA expression in PBMCs and serum samples could be due to the 
different qRT-PCR methods used. In serum samples, miRNAs were detected using the 
miScript PCR SYBR Green detection kit. This method uses SYBR Green I dye that 
intercalates into double-stranded cDNA, as well as into non-specific reaction products, and 
emits a fluorescent signal that is directly proportional to the amount of PCR product 
generated (Rajeevan et al., 2001). On the other hand, miRNAs in PBMCs were detected 
using TaqMan primers and specific probes to the miRNAs of interest. This method detects 
only specific amplification products (Ponchel et al., 2003). Thus differences of miRNA 
expression profiles in PBMCs and serum could be due to variable sensitivity and specificity 
of the validation platforms used (Bustin and Mueller, 2005).  
 
Another factor to consider is the miRNA expression profile in different biological fluids. Wang 
et al. (2012) investigated the expression of miRNAs in serum, plasma and blood 
components (red blood cells (RBC), white blood cells (WBC) and platelets) of six healthy 
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individuals. Their study showed that more miRNAs were detected in blood cells, ranging 
from 280 and 477 miRNAs compared to serum and plasma, where only 118 miRNAs and 
106 miRNAs were detected, respectively. The most abundantly expressed miRNAs (miR-
126, miR-16 and miR-150) in blood cells were equally expressed in serum and plasma 
samples, while the most abundantly expressed miRNA in serum was observed at much 
lower levels in RBC (Wang et al., 2012). Therefore, although biofluids share similar miRNA 
profiles, their patterns differ according to tissue and cell type, which may be due to 
differential uptake or release of miRNAs from different circulating cell types in the blood 
(Maldovan et al., 2014). 
 
Despite these discrepancies, to our knowledge, this study is the first to demonstrate the 
differential expression of miR-27b in PBMCs and serum of pre-diabetic and normo-
glycaemic individuals, thus, illustrating its potential as a biomarker of pre-diabetes. Other 
studies have shown the association of miR-27b with a wide range of cancers, CVD, 
adipogenesis, atherosclerosis, T1D and diabetic nephropathy (Bi et al., 2015; Goto et al., 
2014; Karbiener et al., 2009; Kong et al., 2014; Lehmann et al., 2015; Veliceasa et al., 2015; 
Zampetaki et al., 2015). Using genome wide microarray analysis and qRT-PCR, Lin et al. 
(2009a) showed significant downregulation of miR-27b during adipogenesis, consistent with 
other literature (Karbiener et al., 2009). Over expression of miR-27b inhibits adipocyte 
formation, without affecting myogenic differentiation, suggesting its role in the pathological 
development of obesity (Lin et al., 2009a). Moreover, miR-27b was one of 12 miRNAs 
investigated in serum of diabetic, obese-diabetic, and healthy individuals (Pescador et al., 
2013). However, no significance in miRNA expression was observed between these groups. 
MiR-27b was significantly upregulated in serum of T1D patients compared to healthy 
individuals, illustrating a possible role in β-cell apoptosis and β-cell regulatory networks 
(Nielsen et al., 2012). Li et al. (2010) showed the significant upregulation of three miRNAs, 
including miR-27b in the serum and tissue of patients with atherosclerosis compared to 
healthy controls, as evidence for a possible risk marker in the early stages of atherosclerosis 
(Li et al., 2011). Results of these studies illustrate a possible role of miR-27b in T2D-related 
complications. However, data directly linking miR-27b to pre-diabetes and T2D is still 
lacking. 
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4.9 MiR-27b as a potential biomarker for Pre-diabetes 
Both sequencing and qRT-PCR showed a significant increase in the expression of miR-27b 
in PBMCs and serum of pre-diabetics compared normo-glycaemic individuals. These results 
suggest that miR-27b could be used as a potential biomarker for pre-diabetes; the early 
stages of T2D development that precedes overt diabetes. Individuals with pre-diabetes have 
a 3 to 10–fold increased risk of developing T2D (Garber et al., 2008), and the identification of 
these individuals in the early stages could delay or prevent disease progression through 
lifestyle interventions or therapeutic strategies to reverse progression. However, due the 
limitations of this study and the extensive heterogeneity and non-specificity of miRNAs 
(Turchinovich et al., 2012), validation of miR-27b will be required in a larger cohort and in 
different populations to confirm its potential as a biomarker to identify those at risk for T2D.  
 
It is currently suggested that a biomarker should be involved in disease progression. MiR-
27b was not increased in diabetics, compared to pre-diabetics and normo-glycaemics, 
suggesting an alteration associated with a specific physiological state in the disease. Unlike 
intermediate biomarkers, which represent direct steps in the causal pathway of disease, 
circulating biomarkers represent changes in biological factors that lead to the disease 
(Mayeux, 2004), and are used as indicators of disease susceptibility. Thus, these biomarkers 
need not always be causal, and may merely reflect the subclinical stage of disease to be 
considered useful for screening and prevention. 
4.9.1 Molecular mechanism of miR-27b 
Both computational prediction programs and experimental studies have identified Pparg as a 
target for miR-27b. The positive effect of PPARG on insulin signaling has been widely 
reported (Leonardini et al., 2009). Our results suggest that upregulation of miR-27b in pre-
diabetics suppress PPARG activity by inhibiting Pparg with negative effects on insulin 
signaling and subsequent glucose uptake. The effects of insulin on glucose uptake is 
mediated by phosphorylation of the tyrosine kinase insulin receptor, which leads to 
increased IRS-1–associated PI3K activity, and subsequent translocation of GLUT4 from 
cytoplasmic vesicles to the cell membrane, and uptake of glucose into the cell, thereby 
reducing overall blood glucose concentrations (Chakraborty et al., 2014). Dysregulation of 
intracellular proteins involved in the insulin signaling cascade leads to the development of 
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IR, characterized by high insulin and glucose concentrations. Indeed, insulin and glucose 
levels were increased in pre-diabetics compared to normo-glycaemics (Fig 4.1).   
 
Using a Cre-loxP system for the deletion of Pparg in mouse skeletal muscle, Hevener et al. 
(2003) showed that mice with a Pparg deletion exhibited glucose intolerance and 
progressive insulin resistance after four months. Furthermore, using a hyperinsulinaemic-
euglycaemic clamp, these authors showed a 80% reduction in insulin-stimulated glucose 
uptake in vivo, thus, confirming the crucial role that PPARG plays in skeletal muscle insulin 
action (Hevener et al., 2003). Verna et al. (2004) showed that inhibition of Pparg in C2C12 
skeletal muscle cells induced insulin resistance under normal conditions, while 
overexpression of Pparg in the presence of insulin and/or Pioglitazone (anti-diabetic drug) 
stimulation increased glucose uptake under both normal and insulin resistant conditions 
(Verma et al., 2004).  
 
Consistent with our findings, other studies showed the regulatory effect of miR-27b on 
Pparg. For example, transient transfection of miR-27b in human multipotent adipose-derived 
stem cells decreased the expression of adipogenic markers including Pparg (Karbeiner et 
al., 2009). Using the Dual-Luciferase assay, Karbeiner et al. (2009) demonstrated that miR-
27b directly binds to the 3‟ UTR of human Pparg, thereby decreasing PPARG protein levels, 
and inhibiting adipogenesis. Similarly, the expression of miR-27b in 3T3-L1 pre-adipocytes, 
inhibit both PPARG and CCAAT-enhancer-binding protein α (C/EBPα), thus, confirming its 
role as an adipogenic inhibitor (Lin et al., 2009). Moreover, miR-27b also targets Pparg in 
neuroblastoma cells, which leads to neuroblastoma growth inhibition, associated with 
decreased Pparg target gene expression, and reduced inflammatory responses. In the 
absence of miR-27b, Pparg promotes tumour formation in neuroblastomas (Lee et al., 2012). 
Together, these studies suggest that disease progression associated with impaired PPARG 
signaling is often accompanied by the ability of miR-27b to bind to Pparg and decrease 
mRNA and protein expression. 
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Figure 4.1 Schematic representation of the insulin signaling pathway and a possible role of miR-
27b.The peroxisome proliferator-activated receptor gamma (PPARG) stimulates the insulin signaling 
pathway, which leads to the translocation of glucose transporter 4 (GLUT4) vesicle to the plasma 
membrane, allowing glucose uptake into the cell. The negative effect of miR-27b on PPARG causes 
dysregulation of insulin signaling proteins (insulin receptor substrate 1 (IRS-1) and kinase/serine-
threonine protein kinase-1 (PI3K/AKT)), thereby preventing glucose uptake. 
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4.10 Limitations 
Our study has a number of limitations. These include the small sample size and the absence 
of data for environmental factors that are known to affect miRNA expression. The small 
sample size was due to a number of factors including 1) the challenge to recruit diabetic 
individuals that were not on treatment, 2) the requirement of matching participants for 
ethnicity, age, gender and BMI, and 3) the high cost of sequencing. The primary goal of 
diabetic treatment is to restore glucose homeostasis. However, changes in glucose 
concentrations are known to alter miRNA expression patterns. For example, increased 
miRNA (miR-192 and miR-193b) expression levels in serum of pre-diabetics compared to 
T2D individuals was decreased after chronic exercise, illustrating the effects of glucose 
control on miRNA expression (Parrizas et al., 2014). Matching participants in each group 
was necessary to reduce variability between individuals, and to further minimize confounding 
and bias. The requirement to match individuals for ethnicity, age, gender and BMI limited the 
number of individuals that could be studied. The high cost of sequencing prevented the 
analysis of a larger sample set.  Large sample sizes are required to account for inter-
individual heterogeneity between samples, and to attain clinical significance. 
 
In addition, our study was limited by the lack of data regarding diet, physical activity, and 
behavior such as smoking and alcohol consumption, as these factors are well known to 
contribute to changes seen in miRNA expression patterns. 
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4.11 Future work 
The results of this study will form the basis for future work to explore the role of miRNAs in 
the pathogenesis of T2D. Studies should be conducted in larger cohorts and in different 
populations to investigate the potential of miRNAs such as miR-27b as biomarkers to identify 
those at high risk of developing T2D, and to facilitate intervention strategies that can prevent, 
delay or reverse disease progression. However, due to the extensive heterogeneity of 
miRNAs, and their ability to bind multiple targets, future investigations should focus on a 
panel of T2D-specific miRNAs to identify high risk individuals. 
 
The biological role and cell-type specificity of miR-27b and the novel miRNAs could be 
investigated by conducting gain-of-function and loss-of-function experiments in the four 
major cell-types associated with T2D, i.e., pancreatic β-cells, skeletal muscle cells, 
hepatocytes and adipocytes. For example, miRNA mimics and inhibitors could be 
transfected into pancreatic β-cells to investigate their effects on insulin secretion. Using a 
similar strategy, Tang et al. (2009) reported decreased glucose-stimulated insulin gene 
transcription in β-cells (MIN6) after miR-30d inhibition (Tang et al., 2009). A number of 
miRNA target genes are involved in insulin signaling (Granjon et al., 2009), thus their 
biological role could be investigated by transfection studies in skeletal muscle cells to 
measure the effectes of glucose metabolism under normal and insulin resistant conditions. 
The role of miRNAs in hepatocytes (Herrara et al., 2010) and adipocytes (Hilton et al., 2013) 
have been described, thus transfection experiments in hepatocytes and adipocytes could 
elucidate the molecular mechanism of these miRNAs. 
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4.12 Conclusion 
In conclusion, we showed that miRNA profiles differ during T2D progression, and are able to 
discriminate between diabetic, pre-diabetic and normo-glycaemic individuals. Despite the 
limitations of the study, as alluded to previously, this study showed that miR-27b is 
differentially expressed in both PBMCs and serum of pre-diabetic compared to normo-
glycaemic individuals. These findings demonstrate the importance of miR-27b in the 
pathophysiology of T2D and suggest its potential as a biomarker that could be incorporated 
into predictive models for the identification of high risk individuals with glucose dysregulation. 
Such strategies could facilitate interventions to prevent or better manage T2D, ultimately 
reducing the disease burden. These predictive models could include miRNA expression 
patterns and other known risk factors for pre-diabetes or T2D. However, miRNA profiling in a 
larger sample size and prospective longitudinal studies are required to assess clinical 
applicability. 
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Appendix 2: Consent form 
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Appendix 3: RNA quality control and assessment 
 
Table A3.1 Total RNA quantification and quality assurance by NanoDrop ND-1000 spectrophotometer 
Sample Name OD260/280 Ratio Conc. (ng/µl) Volume (µl) Total Amount 
(ng) 
1 1.81 121.96 10 1219.6 
2 1.73 123.19 10 1231.9 
3 1.81 133.72 10 1337.2 
4 1.78 175.11 10 1751.1 
5 1.78 150.92 10 1509.2 
6 1.87 124.07 10 1240.7 
7 1.76 88.53 10         885.3 
8 1.78 162.49 10 1624.9 
9 1.78 138.24 10 1382.4 
10 1.71 64.37 10         643.7 
11 1.80 130.06 10 1300.6 
12 1.79 147.66 10 1476.6 
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Table A3.2 Quality assessment of the sequencing library, determined by Agilent 2100 Bioanalyser 
using the Agilent DNA 1000 chip kit (Agilent technologies). 
Sample Name Size (bp) Conc. (nmol/L) Conc. (ng/µl) Volume (µl)** Total Amount 
(ng) 
1 142 54.2 5.08 
 
20 101.6 
2 
 
140 
 
54.5 
 
5.03 
 
20 100.6 
3 
 
141 
 
53.3 
 
4.95 
 
20 99.0 
4 
 
140 
 
59.4 
 
5.49 
 
20 109.8 
5 
 
140 
 
66.1 
 
6.12 
 
20 122.4 
6 
 
141 
 
52.8 
 
4.93 
 
20 98.6 
7 
 
141 
 
39.4 
 
3.67 
 
20 73.4 
8 
 
142 
 
53.8 
 
5.04 
 
20 100.8 
9 
 
141 
 
34.5 
 
3.22 
 
20 64.4 
10 
 
142 
 
89.6 
 
8.38 
 
20 167.6 
11 
 
141 
 
58.0 
 
5.41 
 
20 108.2 
12 
 
141 
 
63.2 
 
5.86 
 
20 117.2 
**The concentration of each library was adjusted to 10nM before cluster generation 
 
.  
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Appendix 4: Protein-protein interactions 
Protein-protein interactions possibly regulated by the differentially expressed miRNAs were 
investigated using the protein interaction database called STRING. The red nodes represent 
the target protein of interest, which interact with a number of functional proteins predicted 
using different sources of evidence. The different colour lines indicate different prediction 
methods such as, fusion evidence (red), neighbourhood (green), co-occurrence (blue), 
experimental evidence (purple), text-mining (yellow), database evidence (light blue) and co-
expression (black). 
MicroRNA target gene/protein Functional protein-protein interaction network 
 
 
 
Vascular endothelial growth factor 
C (VEGFC) 
 
 
 
 
 
Peroxisome proliferator-activated 
receptor gamma (PPARG) 
 
Table A4 Functional protein-protein interactions determined by STRING. 
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Insulin receptor (INSR) 
 
 
 
 
 
 
 
 
Tuberous sclerosis 1 (TSC1) 
 
 
 
Mitogen-activated protein 4 kinase 
3 (MAP4K3) 
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Unc-51-like kinase (ULK2) 
 
 
 
 
 
 
 
Stearoyl-CoA desaturase (SCD) 
 
 
 
 
 
 
RPTOR independent companion of 
mTOR (RICTOR) 
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TAO kinase 2 (TAOK2) 
 
 
 
 
 
 
 
 
 
v-Ki-ras2 Kirsten rat sarcoma 
viral oncogene homolog (KRAS) 
 
 
 
 
 
 
 
Fibroblast growth factor 1 (FGF1) 
 
 
 
 
 
 
Protein kinase C, epsilon 
(PRKCE) 
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Calcium channel, voltage-
dependent, P/Q type, alpha 1A 
subunit (CACNA1A) 
 
 
The names of proteins that interact with predicted miRNA targets are as follows: 
 VEGFC; fms-related tyrosine kinase 4 (FLT4), kinase insert domain receptor (KDR), 
neuropilin 2 (NRP2), fms-related tyrosine kinase 1 (FLT1) and insulin-like growth 
factor 1 receptor (IGF1R). 
 PPARG; peroxisome proliferator-activated receptor gamma (PPARGC1A), mediator 
complex subunit 1 (MED1), nuclear receptor coactivator 1 (NCOA1), E1A binding 
protein p300 (EP300), nuclear receptor corepressor 1 (NCOR1), nuclear receptor 
coactivator 2 (NCOA2), histone deacetylase 3 (HDAC3), leptin (LEP), adiponectin 
(ADIPOQ) and nuclear receptor corepressor 2 (NCOR2). 
 INSR; insulin receptor substrate 1 (INS1), protein tyrosine phosphatase non-receptor 
type 1 (PTPN) , SHC (Src homology 2 domain containing) transforming protein 1 
(SHC1), insulin receptor substrate 2 (IRS2), growth factor receptor-bound protein 10 
(GRB10), growth factor receptor-bound protein 14 (GRB14), insulin (INS), 
phosphoinositide-3-kinase regulatory subunit 1 (alpha) (PIK3R1), protein tyrosine 
phosphatase non-receptor type 11 (PTPN11) and suppressor of cytokine signaling 3 
(SOCS3). 
 TSC1; tuberous sclerosis 2 (TSC2), Ras homolog enriched in brain (RHEB), v-akt 
murine thymoma viral oncogene homolog 1 (AKT1), mechanistic target of rapamycin 
(mTOR), v-akt murine thymoma viral oncogene homolog 2 (AKT2), ribosomal protein 
S6 kinase, 90kDa, polypeptide 1 (RPS6KA1), inhibitor of kappa light polypeptide 
gene enhancer in B-cells (IKBKB), v-akt murine thymoma viral oncogene homolog 3 
(AKT3), cyclin-dependent kinase 1 (CDK1) and RPTOR independent companion of 
mTOR (RICTOR). 
 MAP4K3; debrin-like (DBNL) 
 ULK2; RB1-inducible coiled-coil 1 (RB1CC1), autophagy related 13 (ATG13), 
mechanistic target of rapamycin (mTOR), regulatory associated protein of mTOR, 
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complex 1 (RPTOR), GABA(A) receptor-associated protein-like 2 (GABARAPC2), 
GABA(A) receptor-associated protein (GABARAP) and autophagy related 9A 
(ATG9A) 
 SCD; ubiquitin C (UBC), sterol regulatory element binding transcription factor 1 
(SREBF1), peroxisome proliferator-activated receptor alpha (PPARA) and 
cytochrome b5 type A (CYB5A) 
 RICTOR; mechanistic target of rapamycin (mTOR), mitogen-activated protein kinase 
associated protein 1 (MAPKAP1), v-akt murine thymoma viral oncogene homolog 1 
(AKT1), proline rich 5 like (PRR5L), mTOR associated protein (MLST8) and 
eukaryotic translation initiation factor 4 binding protein 1 (EIF4BP1) 
 TAOK2; mitogen-activated protein kinase 3(MAP2K3) and mitogen-activated protein 
kinase 6 (MAP2K6) 
 KRAS: v-raf-1 murine leukemia viral oncogene homologue 1 (RAF1), epidermal 
growth factor receptor (EGFR), ral guanidine nucleotide dissociation stimulator 
(RALGDS), phosphatidylinositol-4-5-bisphosphate 3-kinase (PIK3CA), Son of 
sevenless homolog 1 (SOS1), B-cell CLL/lymphoma 2 (BCL2), protein tyrosine 
phosphatase, non-receptor type 11 (PTPN11) and tumor protein p53 (TP53). 
 FGF1; fibroblast growth factor receptor 1 (FGFR1), fibroblast growth factor receptor 2 
(FGFR2) , fibroblast growth factor receptor 4 (FGFR4), fibroblast growth factor 
receptor 3 (FGFR3), S100 calcium binding protein A13 (S100A13) and fribroblast 
growth factor 23 (FGF23) 
 PRKCE; 3-phosphoinositide dependent protein kinase-1 (PDPK1), voltage-
dependent anion channel 1 (VDAC1), v-raf murine sarcoma viral oncogene homolog 
B1 (BRAF) and ras homolog family member A (RHOA) 
 CACNA1A; calcium binding protein 1 (CABP1), calcium channel voltage dependent 
beta-4 subunit (CACNB4) and guanine nucleotide binding protein (GNB1) 
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